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Abstract 
The oxysterol-binding protein/OSBP-related proteins (OSBP/ORPs) are a family of 
proteins conserved in all eukaryotes that have complex biological activities connected to 
lipid transport and lipid regulation. OSBP is ubiquitously expressed in tissues and is 
required in the replication of a broad array of pathogenic Enterovirus species. 
Alternatively, ORP4L is only expressed in a few select tissues and plays an important 
role in the proliferation and viability of certain cancers. Although the OSBP/ORPs have 
been reported to interact with an array of ligands, including various sterols, phospholipid 
compounds, and natural product compounds, the comprehensive characterization of 
ligand binding to the OSBP/ORP proteins has not been performed. Additionally, this is 
the first binding study on human OSBP and ORP4L, an important step for designing 
ligands for therapeutic targeting of the ORPs. The goal of this research is to characterize 
the ligand binding of human OSBP and ORP4. We utilized two experimental approaches 
to understand the small molecule ligand binding ability of OSBP and ORP4L. The first 
experimental approach was to determine binding affinities of multiple classes of potential 
ligands for OSBP and ORP4L, which was accomplished through the implementation of 
a high-throughput ligand binding assay using cloned and expressed human OSBP and 
ORP4L proteins. Through screening oxysterols for ligand binding, specific sites of 
oxysterol side chain oxidation were identified as being critical for high-affinity 
interaction with OSBP and ORP4. Specifically, oxysterols that show high-affinity 
binding with OSBP and ORP4L have hydroxyls at the C20, C24, C25, C26 or C27 
positions, but not at the C22. The importance of the side chain in oxysterol binding was 
further determined by testing a series of 20-hydroxycholesterol analogs produced in our 
xvi 
lab. The second experimental approach employed was to construct and test a structural 
model of how OSBP interacts with its small molecule ligands, specifically the natural 
product compound OSW-1. Using the existing partial OSBP/ORP structures from yeast 
orthologs, we constructed a model for OSW-1-OSBP interactions. The tentative model 
was used to identify OSBP potentially critical residues that are essential for OSW-1 
binding, and the identified amino acids were selected for mutation. One OSBP point 
mutant was successfully cloned, expressed and tested for ligand binding. The OSBP 
H522A mutant negatively affects OSW-1 binding while not affecting oxysterol binding, 
which supports our interaction model. The results of these projects inform us of how small 
molecule ligands bind OSBP and ORP4L, and perhaps by analogy the other OSBP/ORPs. 
These research accomplishments will aid in the design of new generations of OSBP/ORP 
binding small molecules, including potentially novel anti-cancer and anti-viral 
compounds for therapeutic development to selectively target only OSBP or only ORP4. 
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Chapter 1: OSBP and OSBP-Related Proteins (ORPs)  
1.1 Overview  
Oxysterol binding protein (OSBP) and OSBP-related proteins (ORPs) are 
expressed in eukaryotes.1 These proteins have conserved ligand-binding domains, and the 
different OSBP/ORP members appear to undertake separate biological functions.2 
Recently, this protein family has become the focus of drug development projects.2 The 
research in this dissertation is focused on characterizing the small molecule ligand 
binding to individual OSBP/ORPs, specifically OSBP and ORP4L, and how ligand 
binding modulates the biological activity of the OSBP/ORPs. The introduction will cover 
OSBP/ORP protein biochemistry, cellular function, known ligand binding, and 
connections to disease biology.   
Figure 1: OSBP/ORP Family divided by subfamilies 
Domain graphs were based off full-length Oxysterol Binding Protein (OSBP) and 
the OSBP-related protein (ORP). The graphs were generated and aligned at the 
beginning of their ligand domain, using DOG2.0. The tree was generated using 
amino acid percent identity of OSBP/ORP ligand binding domains using Jalview 
bioinformatics software. 
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1.2 Overview of the OSBP/ORPs 
1.2.1 Overview  
Most of the OSBP/ORP proteins are cytosolic lipid binding proteins.3 Humans 
have 12 ORP genes, and through alternative splicing, at least, 16 protein variants are 
expressed.4,5 The proteins can be grouped, based on their amino acid sequence, into six 
distinct subfamilies (Figure 1).4–7 In humans, cellular expression, and tissue distribution 
vary depending on the ORP. We are beginning to learn the function and molecular 
interaction of many of these proteins, but there is still much that is unknown.  
1.2.2 History of the OSBP and ORPS 
In 1981, OSBP was discovered in the search for the major regulator in cholesterol 
synthesis.8–10 Its most notable feature was its ability to bind 25-OHC.8 OSBP was not the 
influential oxysterol-mediated regulator of cholesterol biosynthesis; SREBP was 
discovered to be responsible for this function.11 These initial experiments involved 
purifying cellular OSBP and testing its binding against sterols.12,13 The first attempts to 
understand the properties of OSBP, involved recombinant rabbit OSBP and revealed that 
deleting amino acids 455 to 809 eliminated binding.14 In the mid-1990s, the first yeast 
genes that are paralogs of the OSBP were identified.15,16 ORP4 was first identified as 
OSBP2 and cloned of monkey retinal cells.17 Then by 2000, the remaining human ORPs 
were documented.4,18 The first indications that  OSBP/ORPs were potentially druggable 
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targets came in 2011 when OSBP and ORP4L were shown to be the targets of 
antiproliferative compounds.19  
1.2.3 Properties of OSBP/ORPs 
The OSBP/ORPs have come in varying lengths but overall have a standard 
organization. The OSBP/ORPs have localizing domains and motifs on their N-terminal 
halves. The most common feature of OSBP/ORP is the large ~50KDa ligand binding 
domain (LBD) which is located on the C-terminal end of the protein.4,18 The second most 
common domain for this family of proteins is the pleckstrin homology (PH) domain.4 The 
PH domain is generally known for its ability to bind to phospholipid on membranes.20 
The PH domains for different OSBP/ORPs are still not fully understood, as the 
localization sites vary depending on the protein.21 There seem to be other factors that 
affect cellular localization.22 All the OSBP/ORPs, except for ORP2, possess this domain.  
ORP2 is the smallest OSBP/ORP containing only an LBD.23 The third most common 
feature of the OSBP/ORPs is the diphenylalanine in an acidic tract (FFAT), its consensus 
sequence is EFFDAxE.24 This motif allows for proteins to associate with the endoplasmic 
reticulum (ER) by binding vesical associate proteins (VAP). Additionally, ORP3 possess 
an FFAT-like motif, which also helps it associate with VAP proteins.25 Two of the human 
OSBP/ORP proteins that do not have FFAT motifs, ORP5 and ORP8, instead contain 
transmembrane (TM) domains that keep them tethered to the ER.26,27 By possessing the 
FFAT or the ER-bound TM, OSBP/ORPs appear to have near universal interaction with 
ER. ORP10 and ORP11 do not have FFAT motif or TM domains and do not appear to 
interact with the ER directly. The dual membrane subcellular regions that ORPs localize 
too are referred to a membrane contact sites (MCS). The rarest feature found in the human 
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ORP family is the ankyrin repeat domain (ANK) found in the long version of ORP1 
allowing it to associate with late endosomes (LE).28–30  
1.2.4 Structural Biology of the Anchoring Domains and Motifs 
The PH domain is 100 – 120 amino acid long domain that has been associated 
with phosphoinositide binding. The only determined structures of human OSBP/ORP PH 
domains are from ORP8 and ORP11 (Figure 2).31,32 The general structure of this domain 
is two seven stranded anti-parallel beta sheets sandwiched together and C-terminal 
amphipathic helix.33 The beta sheets are connected through various loops that are 
essential for binding phosphates. The PH domain is electrostatically polarized, where the 
bottom of the beta sheets and the connecting loops have a net positive charge, which 
allows it to bind negatively charged groups likes phosphates.33 
Figure 2: PH Domains of ORP8 and ORP11 
Structures of two human OSBP/ORP PH domains that have been solved. The 
structure of ORP8 has been solved through X-ray crystallography (PDB: 5U77, 
DOI: 10.2210/pdb5U77/pdb).31 The structure of ORP11 was solved through NMR 
(PDB: 2D9X, DOI: 10.2210/pdb2D9X/pdb).32 Molecular graphics were generated 
with UCSF Chimera. 
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FFAT is a seven amino acid sequence that is known for binding VAP proteins. 
The general consensus sequence of EFFDAxE. So far, the only human OSBP/ORP FFAT 
motifs that have been determined has been of OSBP.34 These studies show that the VAP-
FFAT interactions are held together through hydrogen bonding and that the first 
phenylalanine locks into a hydrophobic pocket in VAP.34  
ORP1L is unique among the human OSBP/ORP family for having an N-terminal 
Ankryin repeating domain (ANK). This domain composes the first 237 residues of 
ORP1L. Currently, the only ORP ANK that has its structure solved is of the yeast 
homolog Osh1.35 However, the Osh1 ANK has low sequence homology to the ORP1 
ANK and are also known to have different interacting partners.35 The general structure of 
ANK domains is a composite of two alpha-helical subunits that form a hairpin loop 
(Figure 3).35,36 
ORP5 and ORP8 are the only two human OSBP/ORPs that contain TM domains, 
instead of FFAT motifs. The TM domain is a fatty alpha-helix that is 18-19 residues in 
length.21 There is no crystal structure for this domain.   
Figure 3: Example of Ankyrin Repeat (PDB: 5GIK) 
An artificial ankyrin repeat protein represented in a rainbow color pattern to emphasize 
the connected alpha-helical subunits of this domain (PDB: 5GIK, DOI: 
10.2210/pdb5GIK/pdb).36 Molecular graphics were generated with UCSF Chimera. 
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1.2.5 Structural Biology of the Ligand Binding Domain 
The OSBP-related domain (ORD), also known as the ligand binding domain 
(LBD), is a highly conserved and defining feature that all OSBP/ORP proteins possess. 
In the literature, ORD, and LBD are used interchangeably, and for this dissertation, LBD 
will be used. Unfortunately, to date, no human LBD structure has been determined. There 
are LBD crystal structures that have been determined are from the yeast OSBP 
homologue (Osh) proteins (Figure 4), which are from S. cerevisiae Os3, Osh4, and Osh6, 
and K. Lactis Osh1.35,37–39 A generic LBD ranges from 300 - 400 amino acids and contains 
the highly conserved sequence motif EQVSHHP.5 Also, the LBD is large around 50 kDa 
and is a dynamic domain with many flexible segments that allow it to bind a diverse 
number of ligands. Despite these similarities, some differences lead to some specificity 
in ligand binding.  
The full-length Osh3 protein is very large and composed of multiple domains, but 
the LBD is so narrow that it can only bind phospholipids, like PI4P.39 On the other hand, 
Osh4 is a short protein that is only composed of the LBD, which is wide enough to bind 
sterols or phospholipids.37,40 Through X-ray crystallography Osh1 and Osh4 have been 
shown to bind cholesterol and a wide range of oxysterols. Osh6 has only been shown to 
bind PI4P and phosphatidylserine (PS).38  
The LBD begins with a small semi-flexible N-terminal lid region, part of this 
region can be used to interact with certain ligands, like PI4P. The lid then proceeds into 
two alpha helices, which are inside the domain. Both the helices and the β-barrel-like 
structures contribute to the interior aliphatic binding tunnel, that can fit in the acyl chains 
of phospholipids or an entire steroidal compound. The domain ends with a flexible C-
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terminal sub-domain, which forms a flexible hinge and loops back opening of the domain 
Figure 4: Osh Ligand Binding Domains Bound to Lipids  
 (A-H) Crystal structure models of Osh3, Osh4, Osh1, and Osh6 bound 
to lipid ligands (PDB ID numbers are listed next to each LBD).35,37–39 
The ligands are represented as solvent excluding molecular surfaces. (A-
D) Osh proteins bound to phospholipids. (E-H) Osh proteins bound to 
cholesterol or oxysterols. Molecular graphics were generated with UCSF 
Chimera. 
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to function as cover alongside the lid.  
 The lid in Osh3 is fixed in place with the binding motif of (R/K)-(R/K)-X-X-I-
(P/D) which is conserved in OSBP, ORP2, ORP3, ORP4, ORP6, and ORP7.39 In the lid, 
the amide backbone of M660 forms a hydrogen bond with the 1-phosphate of PI4P 
(Figure 5).  The methionine is not conserved, but the ligand-backbone interaction is 
maintained in Os4 and Osh6.39 The PI4P head group binds at the entrance of the 
hydrophobic ligand binding tunnel where a cluster of highly conserved basic residues 
interact keep it in place.39,40 For Osh3, the 4-phosphate group of PI4P form direct 
hydrogen binding with the residues H745, R746 (β-barrel like structure) and R949 (C-
terminal subdomain).39 Residues H745, R746 are part of the conserved fingerprint motif 
of the LBD that is normally two histidines in all human ORPs.41 Residues K717 and 
N720, which are highly conserved in all human and yeast OSBP/ORPs, form part of the 
end of the central helices and are involved in hydrogen bonding the 1-phosphate of 
PI4P.38–40 E945 and R949 are involved in water-mediated hydrogen bond interactions.39 
E945 and R949, along with K941 and R952 form direct interactions with the 
phosphoinositol head group  (Figure 5).39 As for the inositol, the 3-hydroxyl forms a 
water-mediated hydrogen bond with the backbone carbonyl of E945, and 4-hydroxyl 
forms a direct hydrogen bond with E945. 39 The long acyl chains of PI4P is housed down 
the hydrophobic binding tunnel.39,40 
For ORP-steroid binding, the promiscuity comes in the LBD’s ability to pack the 
sterol head down, through the hydrophobic binding tunnel, onto a cluster of polar residues 
to accommodate the 3-hydroxyl and for water molecules to lock in the acyl chain 
hydroxyl.35,37,42 Despite having an essential function in the steroidal binding, the polar 
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cluster, at the bottom of the tunnel, is not conserved.21,35,37,39 In Osh 4 the polar cluster is 
N96 forms a direct hydrogen bond with the 3-hydroxyl group, the remainder of the cluster 
is composed of W46, Y97, N165 and Q154 forming water mediate interactions with 3-
hydroxyl and two water molecules.37 Unlike Osh4, the 3-hydroxyl forms two hydrogen 
bonds with two residues, D881 and K1007, in Osh1.35 The bottom Osh1 polar cluster is 
completed with Y912 that forms a water-mediated hydrogen bond with the 3-hydroxyl.35 
Figure 5: Diagram of PI4P Bound Osh3 LBD  
 Molecular interaction diagram of PI4P bound to the Osh3 ligand binding pocket (PDB: 
4INQ).39 The residues that interact with polar groups on PI4P are conserved in the 
yeast and human OSBP/ORPs. The interaction diagram was generated with LigPlot+. 
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Even, though Osh3 is unable to bind sterols, it still possesses a polar cluster Y763, T677, 
N780, and Q799.39  
Phosphatidylserine (PS) binding to Osh6 requires the highly conserved K126 to 
form a water-mediated hydrogen bond and N129 to form a direct hydrogen bond to the 
carboxylate anion of the PS head group.38 The acyl chains of PS dock in the steroidal 
binding pocket, where L64. I67, L69, I73, V124 form hydrophobic interactions.38  H157 
and H158 (fingerprint residues), K182 and K351 are not involved in PS binding but are 
needed for PI4P binding.38  
1.3 Known OSBP/ORP Small Molecule Ligands, Oxysterols, and ORPphilin 
Compounds  
1.3.1 Overview  
The OSBP/ORPs are known to be lipid sensing and lipid transporting proteins.2 
Cells depend on proper lipid regulation and metabolism to function properly.43  Lipids 
provide structural support and can serve as effective relays in signaling pathways.43,44   As 
a result, multiple proteins have evolved to build, metabolize, sense, and bind lipids. A 
significant lipid of interest is cholesterol, which can alter the physical properties of 
cellular membranes, is involved in signaling pathways, and whose metabolites are also 
important an organism’s development.45,46 This subsection will discuss major lipid 
classes that are critical in imparting cellular structure, have roles in signaling pathways 
and are essential in metabolic pathways (Figure 6). This subsection will also cover lipid 
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binding proteins that regulate cholesterol development or are regulated by cholesterol 
metabolites.  
1.3.2 Cellular Lipid Classes 
Fatty acids (FA) are simple lipids that are found in cells and whose basic structure 
is a 12 to 22 carbon acyl chain connected to a carboxylic acid.47 The FA is an 18 carbon 
stearic acid, which is a component in phosphatidylinositide-4-phosphate (Figure 6). 
FA molecules are synthesized with acetyl-CoA and NADPH by the enzyme fatty acid 
Figure 6: Representatives of Each Lipid Group that binds or is regulated by 
the OSBP/ORPs 
Structures of lipids that are representative of the lipids that the OSBP/ORP family 
bind (phospholipids, cholesterol/oxysterols) or regulate.  
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synthase (FAS).48 Fatty acids can be fully saturated or can have unsaturated, possessing 
cis and trans stereochemistry. TG is a major energy-storing molecule and is composed of 
three FA molecules (Figure 6).49 The representative TG in the figure is composed of two 
stearic acids that are saturated with hydrogen, and an arachidonic acid that has unsaturated 
bonds. TG molecules are kept in neutral lipid droplets, which are unique organelles that 
contain a neutral lipid core and phospholipid monolayer surrounding it.49,50  
Phospholipids are a diverse lipid class and are the major component of cellular 
membranes. The basic phospholipid structure is composed of two fatty acids bound to a 
glycerol molecule at C-1, and C-2 position, with the C-3, is bound to a phosphate group.51 
The phosphate is referred to as a head group and can be further modified with other polar 
molecules. The molecules include choline, ethanolamine, serine, glycerol, and inositol.51 
Each of these lipids possesses unique biochemical properties. For signaling, they are 
organized at subcellular positions, including different organelles or the plasma membrane 
(PM).43 The composition of the fatty acyl chains can vary significantly between 
phospholipids and phospholipid classes. Phosphatidylinositol is unique in that it has a 
fixed acyl chain composition consisting of stearic acid at C-1 and an arachidonic acid at 
C-2.52   
All eukaryotic cells contain sphingolipids, and these lipids are essential for proper 
neuronal cell function.53 Sphingolipids are lipids that are like phospholipids in structure, 
but instead of having a glycerol base, they possess a sphingosine base. Sphingosine is an 
amino alcohol with a long hydrocarbon tail and is one of the intermediate products in 
sphingolipid metabolism.54 De novo synthesis of sphingolipids occurs in the ER and 
requires serine palmitoyl transferase to combine palmitic acid and serine, to create 
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dihydrosphingosine.54 Dihydrosphingosine is then converted into dihydroceramide and 
then reduced to ceramide. Ceramide is also synthesized in the ER and transported to the 
Golgi through ceramide transfer protein, where they are used to make sphingomyelin, 
cerebrosides, and gangliosides. Ceramide has been shown to have pro-apoptotic effects, 
inducing ER stress and 
generating 
autophagy/mitophagy.55,56 
Cancer cells can counter the 
effects of ceramide by using 
ceramidase and sphingosine 
kinase to generate 
sphingosine-1-phosphate, 
which stimulates cell division.  
Cholesterol is an 
important lipid with many biological roles and is required in the synthesis of several 
biomolecules. Compared to the other lipid classes, it has a unique fused multi-ring 
structure. The steroidal core has four rings (A, B, C and D ring). Cholesterol also has a 
hydroxyl on carbon 3 of the A ring, and an octyl side chain bound to the D ring and has 
a unique numbering scheme (Figure 7).46 The unique structure of cholesterol makes it 
useful in maintaining plasma membrane fluidity. Cholesterol synthesis is very complex 
and is regulated by many systems, with the enzyme HMG-CoA reductase being the rate 
limiting step.57,58 Overproduction of cholesterol is linked with a heightened risk of 
developing cardiovascular diseases, and atherosclerosis.59 Cholesterol is transferred 
Figure 7: Numbering System for Cholesterol 
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across the body as cholesterol esters (CE), in lipoprotein balls and is stored in neutral 
lipid droplets. Cholesterol is needed for synthesizing vitamin D. Cholesterol is needed to 
synthesize five major classes of steroid hormones: progestogens, glucocorticoids, 
mineralocorticoids, androgens, and estrogens. Cholesterol is needed to make bile acids. 
Lastly, oxidized derivatives of cholesterol, known as oxysterols, are created through 
enzymatic modification, and direct reactions with reactive oxygen species.60 Oxysterols 
are generated in both the synthesis of cholesterol and its metabolism.  
1.3.3 Oxysterols  
Oxysterols are oxidized derivatives of steroidal compounds, primarily of 
cholesterol.60,61 They can be produced enzymatically, as intermediates, in the process 
making cholesterol or its metabolism, and non-enzymatically they are also generated 
through oxidation with reactive oxygen species.60,61 Oxysterols are involved in signaling 
responses, and their dysregulation can have major impacts on immune response, 
potentiate cancers, and facilitate the production of neurological disorders and 
cardiovascular diseases.60,62 The oxysterols that are discussed in this section are 
hydroxycholesterols (OHC) and ketocholesterols (KC), and have been used in 
experiments for this dissertation: 25-OHC, 25(R),27-OHC, 25(S),27-OHC, 24(R)-OHC, 
24(S)-OHC, 22(R)-OHC, 22(S)-OHC, 7α,25-diOHC, 7β-OHC, 19-OHC, 7-KC and 5α-
OH,6-KC.  
25-Hydroxycholesterol (25-OHC), is a derivative of cholesterol with a hydroxyl at C-25, 
is commonly used in studies about cholesterol homeostasis.63 25-OHC can be generated 
from several metabolic enzymes, CYP27, CYP46, CYP3A4, and 25-hydroxylase.64 It has 
also been shown to be produced through the autooxidation of cholesterol but does not 
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appear to be of great biological importance.64 25-OHC and 24S-OHC act as viral 
inhibitors. 7α,25-dihydroxycholesterol (7α,25-diOHC) is a known agonist for the 
Epstein-bar virus.62 20α-OHC, also known as 20(S)-OHC, is a ligand agonist for 
smoothened in the Hedgehog pathway and is suspected to localize at the Golgi.65,66 20α-
OHC has osteogenic properties through its interactions with the Hedgehog pathway.67 
22(R)-OHC is an intermediate, from cholesterol, that is generated in the process of 
making pregnenolone that is further metabolized into hormones.68 22(S)-OHC, on the 
other hand, is not a naturally occurring oxysterol, but synthetically derived and useful in 
biological studies.69 24(S)-OHC, also known as cerebrosterol, is found in high 
concentrations in the brain.70,71 24(R)-OHC, epicerebrosterol, is not as common as its 
isomer and is only known to be formed as an intermediate in the formation of 24,25-
epoxycholesterol.72,73 The nomenclature for oxysterols at C-26 and C-27 is convoluted 
with multiple synonyms for these two compounds found in the literature. For the sake of 
simplicity, hydroxylating at C-26 on cholesterol yields 25(S),27-OHC and yields 
25(R),27-OHC, and will be used for this dissertation. 25(R),27-OHC is a naturally 
occurring oxysterol that is made by CYP27A1 and is the most abundant sterol found in 
atherosclerotic plaques.74,75 7-KC plays a major role in the formation of atherosclerotic 
plaques and is formed through oxidation.75  19-OHC has biological activity but is not a 
biologically occurring metabolite.76 5α-OH,6-KC is a major metabolite from 5,6β-
epoxide oxidation in the lungs.77  
1.3.4 ORPphilins 
ORPphilins a class of structurally diverse compounds that come from a diverse 
array of sources, and target members of the oxysterol-binding protein (OSBP)/OSBP 
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related protein (ORP) family (Figure 8). The natural product versions of these 
compounds were initially noted for their antiproliferative abilities.19 
OSW-1 is a steroidal saponin extracted from the bulb of Ornithogalum 
saundersiae, a flower used in Chinese folk medicine for its medicinal properties.78 The 
OSW-1 structure contains a steroidal core, with disaccharide moiety composed of xylose 
and arabinose capped with a paramethoxybenzoate.79 Initially, OSW-1 was identified as 
an acylated cholestane glycoside that could inhibit cyclic AMP phosphodiesterase.78 
When compared to cardiac glycosides, it was found that OSW-1 did not inhibit arterial 
smooth muscle and epithelial cells in rats.80 However, it was shown that OSW-1 does 
slightly raise FSH levels in rats.81  
OSW-1 was more potent as an antiproliferative compound, and its cytotoxicity 
pattern indicated that it might share a similar mechanism to cephalostatin 1.82 OSW-1 
Figure 8: The ORPphilins 
 Chemical structures of the antiproliferative and antiviral compounds called the 
ORPphilins, this class of compounds includes natural products (1-4) and synthetic 
compounds (5-7).  
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induces caspase eight mediated Bcl-2-cleavage in CHO cells.83  OSW-1 downregulates 
genes in Wnt, MAPK and VEGF signaling pathways, inducing necroptotic death in 
hepatocellular carcinoma cell line Hep3B.84 In leukemia cells, OSW-1 causes an 
elevation in cytosolic Ca2+ levels which triggers the activation of caspase-3, loss of 
mitochondrial membrane potential, mitochondrial damage, the release of cytochrome C 
and the cleavage of survival factor GRP78.85,86 Through pull-down experiments and 
protein mass spectrometry, the target of OSW-1 was identified as OSBP and ORP4L, and 
the inhibition occurred at nanomolar levels.19  OSW-1 inhibits OSBP from exchanging 
PI4P with sterols, 25-OHC does not inhibit this interaction.87  
Cephalostatins are bis-steroidal natural product compounds that were originally 
isolated from a marine worm Cephalodiscus gilchristi.88,89  Cephalostatin 1 was identified 
because of its activity in the murine P388 lymphocytic leukemia system.88 In leukemia T 
Jurkat cells, cephalostatin 1 induces apoptosis through release of Smac/DIABLO, 
inducing the disruption of the mitochondria’s membrane potential.90 However, this did 
not result in the release of cytochrome C or other pro-apoptotic factors, and the 
overexpression of Bcl-xL blocks the apoptotic effects of cephalostatin 1.90 It was also 
observed that cephalostatin 1, induces apoptosis by activating caspase 4 and caspase 9 in 
the process causing ER stress.91 Like OSW-1, cephalostatin was identified to target both 
OSBP and ORP4L with binding interactions at the low nanomolar levels.19  
Ritterazines are bisteroidal natural products that were isolated from the marine 
tunicate Ritterella tokioka.92 Just like cephalostatin 1, ritterazine B showed activity for 
the P388 system.92 Through the COMPARE pattern recognition analysis indicated that 
ritterazine B acts through a similar mechanism of action as cephalostatin 1.93 Ritterazine 
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B is cytotoxic in PC14 NSCLC cells and HL-60 leukemia cells, locking them at the G2/ 
checkpoint.94 Ritterazine B target OSBP selectively with low nanomolar levels, and 
shows weak binding toward ORP4L.19  The selectivity of OSBP over ORP4L indicates 
that it is possible to target individual members of the OSBP/ORP family.  
The schweinfurthins are prenylated stilbenes that were first isolated from an 
African plant, Macaranga schweinfurthii.95 Schweinfurthin A was active in the NCI-60 
cell line human tumor screen, with the brain tumor subpanel being the most sensitive.95 
Schweinfurthin A inhibited proliferation in SF-295 glioblastoma cells and KR158 
astrocytoma cells but had little effect in A549 lung tumor cells and primary astrocytes.96 
In KR158 cells it was shown that Schweinfurthin A alters the actin cytoskeleton and 
inhibits Rho signaling which results in cell death.96 The cytotoxicity profile of 
schweinfurthin A indicated that it had a similar mechanism as cephalostatin 1, OSW-1 
and ritterazine B; and like ritterazine B, schweinfurthin A shows a selectivity for OSBP 
over ORP4L.19 Schweinfurthin G, which is extracted from the fruits of Macaranga 
alnifolia, has been shown to be bioactive as well and can also interact with OSBP and 
ORP1L.97,98  
Itraconazole is a synthetic triazole compound that was developed as an orally 
active antifungal.99 Through screening, itraconazole demonstrated antitumor properties 
that worked by inhibiting the protein smoothened in the hedgehog pathway.100 Most 
recently, itraconazole was identified as broad-spectrum enterovirus replication inhibitor 
that works through by inhibiting OSBP.101 Other synthetic antiviral compounds that have 
been identified to work through OSBP are the enviroxime-like compounds, T-00127-
HEV2 and TTP-8307.102–104 
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1.4 Other Oxysterol Binding Protein Families  
1.4.1 Overview  
Lipids are the major component of membranes and are also important in critical 
signaling pathways. The regulation of lipid levels is crucial for the proper development, 
function, and growth of organisms. The discovery of regulatory proteins and pathways 
has historically been a major focus in biological research. In this section will briefly 
review major proteins and pathways that bind oxysterols and regulate metabolic 
pathways. 
1.4.2 Hedgehog Signaling Pathways  
The hedgehog (HH) signaling pathway is a major developmental pathway in 
eukaryote embryonic development and inhibition of this pathway during development 
results in severe deformations.  The gene was isolated in fruit fly larvae, in which HH 
mutation produced larvae with a spiky appearance.105 In mammals, there are three forms 
of hedgehog: sonic hedgehog (SHH), sonic hedgehog (SHH), Indian hedgehog (IHH) and 
desert hedgehog (DHH).106 SHH has been shown to be localized to the ER where it is 
cleaved.107 Before N-SHH can be secreted, the C-terminal covalently linked to cholesterol 
and the N-terminal half is linked to palmitate.108,109 Secreted HH binds the plasma 
membrane receptor patched (Ptc), resulting in the activation of smoothened (Smo).110 
When HH is absent, Ptc prevents signal transduction by binding to Smo, which is part of 
the G-protein-coupled receptor superfamily.111,112 
Certain cancers have been shown to use hedgehog signaling to stay viable, 
possessing an inactive Pts and an overactive Smo.111,113 Cyclopamine was the first 
observed inhibitor of the HH pathway, doing so by inhibiting Smo.112,114 Smo has two 
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regions where ligands can bind the first being a cytosolic cysteine-rich domain (CRD) 
and the second area is the seven-transmembrane domain when it adopts a heptahelical 
bundle fold.115 Cyclopamine, SANT1, and Vismodegib bind the heptahelical bundle.65 
Oxysterols, especially, 20α-OHC has been shown to function as an agonist for Smo, and 
22-azacholesterol was determined to function as an antagonist that can compete for the 
same binding pocket in the CRD.65 Itraconazole is also HH inhibitor, but it is unknown 
which binding pocket it inhibits.100  
1.4.3 SREBP Pathway 
Sterol Regulatory Element-Binding Protein (SREBP) is a transcription factor that 
regulates the production of fatty acids, phospholipids, triglycerides, and cholesterol.116,117 
SREBP is a basic-helix-loop-helix-leucine zipper family and is synthesized in an inactive 
form that is bound to the ER, through its transmembrane domain.118,119 SREBP forms a 
complex with SREBP cleavage-activating protein (SCAP), which is required for 
activation of SREBP which is accomplished through proteolytic processing.120 SCAP can 
sense cholesterol levels when levels are low SCAP escorts SREBP toward the Golgi 
apparatus. SREBP is then cleaved Site-1 protease (S1P) and Site-2 protease (S2P), where 
it translocates to the nucleus and upregulates genes involved in cholesterol/lipid uptake 
and synthesis.121,122 Insulin-induced gene 1 protein (INSIG) negatively regulates the 
SCAP-SREBP complex. When ER cholesterol levels are too high, SCAP will bind 
cholesterol which causes it to go a conformational shift and binds to INSIG.123 Another 
level of regulation is found through 25-OHC binding to INSIG making at bind to SCAP-
SREBP complex.123 Both modes of inhibition have the same effect, of trapping SCAP in 
the ER and preventing SREBP from being activated. SREBP is upregulated by 
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transcription factors known as orphan nuclear receptors.124 In macrophages, 
overproduction of cholesterol causes it to be shuttled into the mitochondria leading to 
damage and the overexpression of interleukin 1β causing inflammation.125 25-OHC levels 
can negatively regulate SREBP2 to abrogate this effect.125 
1.4.4 Liver X Receptors 
Liver X receptors (LXR) are major transcription factors that regulate lipid, 
lipoprotein, and carbohydrate metabolism.126 Initially, LXR was categorized as an orphan 
nuclear receptor, until oxysterols, especially 24(R)-hydroxycholesterol, were shown to be 
their ligands.127,128 Upon binding oxysterols, LXR forms an obligate heterodimer with 
retinoid X receptor (RXR). This complex then translocates to nuclease and upregulates 
genes required for the synthesis of cholesterol and fatty acids.129  LXR has two isoforms 
LXRα and LXRβ, and share 80% amino acid identity in their DNA-binding and ligand-
binding domains.126 LXRα controls cholesterol metabolism and lipoprotein regulation in 
metabolically active tissues like the liver, small intestine, kidney, macrophages, and 
adipose tissue.126 LXRβ has been shown to be important in immune system regulation 
and maintaining cholesterol homeostasis in the central nervous system.130  
1.5 The OSBP/ORPs in Human Disease  
1.5.1 Overview  
As previously discussed, each OSBP/ORP has a unique role to ensure healthy 
cellular function. Currently, some OSBP/ORPs, (OSBP, ORP4L, ORP5) appear to be 
very promising targets for drug development and inhibiting other OSBP/ORP members 
may lead to unintended side effects.19,101,102,131–133 The OSBP/ORPs have highly 
conserved sequences, bind many of the same ligands, but each member has a unique 
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biological role. In this section, we review the relationship between aberrant OSBP/ORP 
levels or loss of function mutations resulting in the manifestation of diseases and genetic 
disorders.   
1.5.2 Subfamily-I: OSBP and ORP4  
In 2011, it was shown that Oxysterol Binding Protein (OSBP) was the target of 
anti-proliferative natural products.19 OSBP inhibition also has been shown to weaken 
some viral infections. Primarily, enteroviruses and hepatitis C virus (HCV) require OSBP 
to replicate virus particles.101,134 When these viruses infect a host, they have been shown 
to build new compartments from their host’s organelles. These new compartments are 
called membranous webs or replication organelles (RO).101,134 OSBP, which normally 
localizes to the MCS between the ER and Golgi, is recruited to the RO and ER MCS 
instead.101 HCV uses an ER-anchored non-structural protein to guide both VAP and 
OSBP into its desired position.135 HCV requires also requires that OSBP and CERT be 
unphosphorylated, and so knocks down the expression of protein kinase D (PKD) to 
ensure this is the case.136 OSBP is believed to enrich the new RO with cholesterol in PI4P 
dependent manner. 101,135  
The VAPB-P56S mutant causes a familial form of Amyotrophic Lateral Sclerosis 
(ALS).  This mutant protein is prone to aggregation and disrupts the traffic between the 
ER and other organelles.137,138 In Drosophila, it was shown that OSBP was unable to bind 
the ALS mutant form of VAP-B, leading to aberrant ER morphology.137 
ORP4 promotes survival for a subset of rapidly dividing cells. For example, RNAi 
silencing of all ORP4 isoforms induces growth arrest, but not cell death in HEK293 and 
HELA cells.139 Silencing ORP4 in IEC-18 cells rapidly induces apoptosis.139 ORP4L 
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mRNA was found to be upregulated in the blood samples of cholangiocarcinoma 
patients.140 ORP4L is expressed chronic myeloid leukemia and is also expressed in many 
metastatic cancers.141,142 ORP4L is most notably T-cell acute lymphoblastic 
leukemia.133,141–143 In leukemia cells, ORP4L acts as a metabolic switch that controls 
whether a cell stays in the citric acid cycle or use lactic acid fermentation.133 ORP4L  
accomplishes this by acting as a scaffold for T-cell receptors, G protein (Gαq/11) which 
then recruit phospholipase C β3.133 This, in turn, leads to the production of inositol 
trisphosphate (IP3) and Ca2+, which lead to the activation of pyruvate dehydrogenase.133 
Expression of ORP4S and ORP4L has been linked with a decrease in HCV infection.144 
1.5.3 Subfamily-II: ORP1 and ORP2  
Macrophages overexpressing ORP1L led to the development of atherosclerotic 
lesions in LDL receptor-deficient mice.145 How ORP1L does this is unknown, but it is 
believed that this mechanism might be through ABCG1, ABCG5 apoE, and PLTP.145 
ORP1L downregulation through microRNA-499a results in decreased levels of serum 
HDL.146 Moreover, expression of a nonfunctional truncation mutant OSBPL1A p.C39X 
led to the low HDL and cholesterol efflux.147 ORP1L is a potential antibacterial target for 
a zoonotic pathogen that causes Query Fever, Q Fever.148 ORP1L is also recruited to the 
parasitophorous vacuoles of Coxiella burnetii.149 C. burnetii is a gram-negative 
intracellular bacterium that uses the large lysosome like vacuoles it forms to 
replicate.148,149  
ORP2 mutations have been associated with deafness. Whole-exome sequencing, 
with cosegregation analysis, identified a heterozygous frameshift mutation, that 
prematurely truncates ORP2, and the missense ORP2L195M mutation are both 
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respectively present in deaf individuals examined.150 Tissue staining shows that outer and 
inner hair cells have clusters of enriched ORP2.151 The mechanism by which ORP2 
causes hearing loss is not fully understood. It appears that the mutations in ORP2 could 
cause misregulation of DIAPH1 and lead to morphological problems in hair cell 
cilia.151,152 It is also possible that the reduction ORP2 may decrease HDL levels, as was 
shown with ORP1, but this hypothesis needs to be experimentally validated.153    
1.5.4 Subfamily-III: ORP3, ORP6, and ORP7  
ORP3 was observed to upregulated as a result of aberrant SUMOylation of liver 
receptor homolog 1 (LRH-1).154 In mice this caused increased activity of SREBP and the 
manifestation of nonalcoholic fatty liver disease.154 ORP3 overexpression has been 
observed in various cancers.155 ORP3 can disrupt the formation of VAPB-P56S 
aggregates, in the process ameliorating its negative effects organelles and the stress that 
leads to ALS.138 Expression of ORP3 and FMO4 correlated with greater overall survival 
of glioblastoma patients, who were being treated with lomustine and bevacizumab.156 
Mutations in ORP3 are associated with metastatic breast cancer.157 Conversely, ORP3 is 
upregulated in pancreatic ductal carcinoma.158  
ORP6 has been associated with dyslipidemia and is located on chromosome 2, 
which has been linked to premature coronary artery disease.159,160 Atherosclerotic plaques 
have been shown to contain a decrease in ORP6 expression.161 Knocking down of ORP6 
results in misregulation of endosomes, reduces the esterification of cholesterol and an 
increase of free cholesterol.161 ORP6 is positively correlated with HDL and apoAI 
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levels.161 Large-scale genome-wide association has identified SNPs in ORP6 can increase 
the risk of Alzheimer’s disease.162  
ORP7 mRNA as upregulated in both tumors induced by Opisthorchis viverrini 
(liver fluke) and was also detected in the blood cells of patients with 
cholangiocarcinoma.140 Genome-wide association studies have linked SNPs in ORP7 to 
increased LDL and total cholesterol levels.163,164 
1.5.5 Subfamily-IV: ORP5 and ORP8  
ORP5 is overexpressed in pancreatic cancers and linked to its invasiveness and 
poor prognosis.131 Preliminary evidence has linked ORP5’s role in pancreatic cancer to 
altered cholesterol metabolism and induced SREBP2 expression.132 Furthermore, it was 
also shown that HDAC5, which also has a sterol response element is involved in the 
ORP5 mechanism.132 These results were determined with the use of statins and HDAC 
inhibitors that showed cell growth reduction in ORP5-positive pancreatic cancer cell 
lines.132  Furthermore, ORP5 was also upregulated in metastatic lung cancers.165 
Knockdown in ORP5 leads to decreased cell proliferation and migration.166 SNPs of 
ORP5 has even been linked to alcohol dependence, along with a cluster of other genes on 
chromosome 11.167 ORP5 expression was shown to correlate to LDL production in the 
leukocytes of healthy human subjects.168  
ORP8, as well as ORP5, has been shown to be involved in lipid regulation and 
metabolism.31,169 In the macrophages of atherosclerotic lesions, both ORP8 mRNA and 
protein are overexpressed compared to healthy cells which lead to suppression of 
ABCA1.27 LDL receptor knock out mice are a common model to study atherosclerotic 
lesion development. Mice injected with bone marrow-derived cells resulted in in 
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increased levels of VLDL and triglycerides and decreased lesion size.170 It was also 
shown that the knockdown of mouse ORP8 yield higher levels of HDL and apoAI.171 In 
gastric and hepatocellular cancers ORP8 expression is knockdown. ORP8 overexpression 
has been shown to induce ER stress in gastric cancers.172 In hepatocellular carcinoma 
cells, ORP8 overexpression induces Fas-mediated apoptosis.173 Moreover, in hepatic 
cancer cells ORP8 is required to maintain the cytotoxic effects of 25-OHC.174 However, 
ORP8 mRNA is overexpressed in the late stages of liver fluke induced 
cholangiocarcinoma progression.140,175 Whether ORP8 induction, in this case, is a 
defensive result of the cell, or physiological requirement of the parasite is not known.   
1.5.6 Subfamily-V: ORP9  
ORP9 mRNA is down-regulated in the poor survival group of subjects with early 
to mid-stage colorectal cancer.176 ORP9 SNPs were correlated to higher incidence of 
atherosclerosis, in cerebral infarction patients, using polymerase chain reaction-
restriction fragment length polymorphism (PCR–RFLP).177 
1.5.7 Subfamily-VI: ORP10 and ORP11  
ORP10 overexpression has been observed in individuals infected with the dengue 
virus.178 Moreover, shRNA knockdown of ORP10 gene expression resulted in significant 
reduction in DENV2 replication. RXRA was also upregulated during dengue infection, 
suggesting the virus’ mechanism of pathogenicity requires ORP10 and the LXR 
pathway.178  ORP10 is connected to dyslipidemia through multiple genetic studies. 
ORP10 silencing was shown to result in increased lipogenesis and apoB-100 secretion in 
hepatic cells.2,179,180 SNPs in ORP10 have been linked to hypercholesterolemia, high 
triglyceride levels, hypertension, and peripheral arterial disease.179,181–183 Regarding 
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cancer diagnostics, ORP10 SNPs have been found in prostate cancers and B-cell 
lymphoma and are potential biomarkers for these diseases.184,185   
The body of research that connects ORP11 with diseases is sparse. There are links 
between SNPs in ORP11 and risk factors for diabetes and cardiovascular disease in obese 
individuals.186 Mutations in ORP11, in combination with mutations in POLR1A, were 
observed in two brothers with a neurological disorder that causes ataxia, psychomotor 
retardation, cerebellar and cerebral atrophy, and leukodystrophy.187 
1.6 Cellular Biology of the OSBP/ORPs 
1.6.1 Overview 
As previously stated, humans have 12 OSBP/ORP genes and with alternative 
splicing can express different isoforms of OSBP/ORP proteins.4 Since their discovery, 
the OSBP/ORPs have remained understudied when it comes to their functions inside 
cells. Advances have been made to understand certain members, e.g., OSBP, ORP1, and 
ORP5, but other members have not yet been studied to the same level of detail.2 Each 
OSBP/ORP member has a unique cellular/tissue expression pattern and is known that 
each ORP has a role in either metabolic sensing or cellular signaling.2 In yeast, ORP 
proteins have been shown to have a functional redundancy in which the total knockdown 
of all ORPs resulted in cell death.188 It appears that this functional redundancy does not 
hold for the human OSBP/ORPs. This section reviews what is known about OSBP/ORP 
cellular functions.  
1.6.2 Subfamily-I: OSBP and ORP4 
OSBP is ubiquitously expressed in tissues. Upon ligand binding, OSBP localizes 
in between the ER and the trans-Golgi.189 The FFAT motif on OSBP recognizes both 
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VAP-A and VAP-B.190 The PH domain weakly recognizes PI4P, but it requires GTPase 
arf1 to localize to Golgi.191 It has been shown that a significant cellular role for OSBP is 
the regulation of cholesterol transport to the Golgi and PI4P to the ER.87,192 This effect 
has been shown to be a four-step cycle in which OSBP, first, localizes in between the ER 
and  Golgi, second cholesterol is shuttled to the Golgi, after which PI4P is shuttled to the 
ER, and finally, the PI4P is hydrolyzed by phosphatase Sac1, which alters the chemical 
gradient in the ER that allows for cholesterol transport to occur.193  
OSBP is also instrumental in the biogenesis of sphingolipids. When translocated 
at the MCS, OSBP binds to CERT. CERT also has a pleckstrin homology domain, that is 
similar to OSBP that recognizes pools of PI4P on the Golgi.194 When localized to the 
Golgi, CERT transfers ceramide to the Golgi, increasing the synthesis of sphingomyelin. 
Increased levels of cholesterol combined with sphingomyelin production, creates an 
enriched microdomain of cholesterol and sphingomyelin that are necessary for the protein 
and lipid sorting, and the secretory pathway.189  
Moreover, OSBP has been observed to function as a scaffold in signaling 
pathways. OSBP has been shown to be involved in ERK signaling; low cholesterol levels 
cause OSBP to coordinates two phosphatases (PTPPBS and PP2A) to dephosphorylate 
pERK.195 It was demonstrated that removing the PH domain, also reduced the complexing 
and dephosphorylation. OSBP has been shown to be phosphorylated by JAK2, recruit 
STAT3 to be phosphorylated resulting in STAT3 translocating to the nucleus.196   
ORP4L is necessary for cellular proliferation and maintaining proper Golgi 
morphology.22 Mice testis lacking ORP4 expression resulted in low sperm numbers and 
of those produced they had low motility and abnormal morphology.197 ORP4 has multiple 
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isoforms, ORP4L has been shown to be necessary for cell proliferation and survival.139 
ORP4L is recruited to localize both at the ER-Golgi MCS and the PM.22 Changing the 
amino acid residues HHK to AAA in the fingerprint motif in the LBD weakens the ability 
of ORP4L to bind to VAP-A on the ER.198 The ER-Golgi association is controllable 
through 25-OHC and is also dependent on the presence of OSBP.22 The association 
between ORP4L and the PM is ligand-independent, interacts in areas that contain 
vimentin and rich in PI4P.22,199 The PH domain appears to regulate the degree at which 
ORP4 interacts with vimentin.139 ORP4M, has an inactive truncated PH domain and acts 
more similarly to ORP4S decreasing its selectivity for PI4P and vimentin localization.139  
ORP4L has selective tissue expression in the brain, heart, and testis.18,197 ORP4L 
may be implicated in regulating the energetics of cells, considering that it affects 
energetics in cancer cells that overexpress ORP4L.133 Moreover, low constitutive 
expression of ORP4 in hepatocytes has been shown to control the formation of lipid 
droplets.144  
1.6.3 Subfamily-II: ORP1 and ORP2 
ORP1 and its transcription variants appear to have roles as a cholesterol sensor 
and endosomal trafficking.200 ORP1L directly interacts Rab7 on LE and alters the 
morphology of this organelle.29 ORP1L functions as a cholesterol sensor for LE and uses 
its FFAT to bind VAP proteins on the ER. ORP1L can transfer the LE cholesterol to the 
ER.201 This transfer requires Niemann-Pick C1 (NPC1) to load cholesterol into the LE 
membrane.201 PI4P is also needed for this cholesterol transfer, ORP1L can bind PI4P, but 
it is not known if this cholesterol is exchanged in a countertransport manner.201 The FFAT 
on ORP1L prevents VAP from removing dynein–dynactin subunit, p150Glued, from the 
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LE.202 ORP1S Upon ligand binding ORP1S translocates to the nucleus and help LXR 
bind regulatory elements and increase transcription.203 Both isoforms have different tissue 
distribution patterns, ORP1L is most abundant in the brain and lungs, and ORP1S has 
higher expression in skeletal muscle and heart.28 ORP1L and ORP1S have increased 
expression in monocytes, with ORP1L expression being higher.28 
ORP2 is ubiquitously expressed in tissues.23 ORP2 binds neutral density 
organelles and may have cholesterol a cholesterol-mediated role in triglyceride 
metabolism.204 The hydrolysis of triglycerides is dependent on the ability of ORP2 to bind 
VAP proteins on the ER.198 Like ORP4L, changing residues HHK to AAA will weaken 
the association between ORP2 and VAP-A.198 ORP2 can translocate to the nucleus and 
help LXR bind regulatory elements and increase transcription of genes that regulate 
glucocorticoid synthesis.205  Moreover, overexpression of ORP2, in stably transfected 
CHO cells, resulted in enhanced cholesterol efflux and decreased levels of esterified 
cholesterol.23 ORP2 is also shown to regulate cytoskeletal actin in hepatocytes.206 This 
ability is most likely due to interactions with diaphanous homologue1 (DIAPH1), a 
protein that binds to actin to affect cell shape and motility.152  
1.6.4 Subfamily-III: ORP3, ORP6, and ORP7 
ORP3 binds actin in the plasma membrane. ORP3 decrease leads to increases in 
PI4P.138 ORP3 is expressed in monocytes, epithelial and neuronal cells.28 ORP3 does not 
have a well-established subcellular localization pattern.2 However, ORP3 can recognize 
sites on the ER and also the plasma membranes.207 Overexpressing ORP3 and VAP cause 
alterations in the morphology of the ER.207 ORP3 has been shown to interact with R-Ras 
altering actin organization and affecting cellular adhesion.155 The effect of ORP3 on R-
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Ras activity depends on ORP3’s phosphorylation state. In order to have proper ORP3-R-
Ras interaction, hyperphosphorylated ORP3 must bind VAP-A and associate to the PM.25 
Overexpression of ORP3 was also positively correlated with Akt phosphorylation.25 
ORP6 is involved in regulating cholesterol efflux and homeostasis by affecting 
the early lysosomal network.2 ORP6 has a two-fold upregulation, in macrophages that are 
loaded with acylated-LDL.5 More recently, ORP6 was shown to be a transcriptional target 
of LXR in macrophages and hepatocytes.161 Conversely, ORP6 is negatively regulated 
by microRNAs, miR-33, and miR-27b.161 ORP6 co-localization was shown to occur 
between the endolysosomal network and the ER, as well as the ER and the PM.161,208 
ORP7 is involved in the autophagosome pathway.209 Treating 293A cells with 25-
OHC causes ORP7 interacts with GATE-16, inducing the degradation of SNARE protein 
GS28.209 ORP7 does not have a well-established subcellular localization pattern.2  
Bimolecular complementation fluorescence (BiFC) has shown the FFAT on ORP7 does 
associate with VAP proteins, upon binding 25-OHC.198  
1.6.5 Subfamily-IV: ORP5 and ORP8 
ORP5 is anchored to the ER via its TM domain, ORP5 has no isoforms, and have 
multiple diverse cellular functions. ORP5 can interact with the  PM  and shuttle in PI4P, 
from the PM, with PS, from ER, in a countertransport.169 ORP5-LBD was shown to bind 
the outer mitochondrial membrane protein PTPIP51.210 This interaction localizes ORP5 
at an ER-mitochondria MCS and induces the delivery of PS to the mitochondria.210 
Silencing ORP5 also causes aberrant mitochondrial morphology and function.210 ORP5 
is also known to interact with LEs and extract cholesterol, loaded by NPC1.26 ORP5L is 
also important in oocyte development, as mutations in ORP5 have been associated with 
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triploidy.211 ORP5 levels are associated with cell proliferation and migration, and in order 
to have this a fully functional LBD is needed.166 ORP5 can localize mTOR to 
lysosomes.166  
ORP8 is most closely related to ORP5 and has been shown to have overlapping 
functions with that protein. ORP8 is bound to the endoplasmic reticulum and localize to 
the mitochondria by binding the outer mitochondrial membrane protein PTPIP51.210 Also 
like ORP5, ORP8 can interact with the PM and drive same PI4P-PS countertransport.169 
It was shown in vitro, that the PS PIP countertransport is possible with multiple PIPs, and 
transport is most efficient with PI3P and PI(4,5)P.31 Increased expression of ORP8 
negatively regulates ABCA1 and cholesterol efflux from macrophages.27 In BiFC 
experiments, ORP8 was shown to interact with Nucleoporin Nup62 and in the process 
suppress the function of SREBP.212 In mouse macrophages it was shown that ORP8-Nu62 
interaction resulted in decreased migration.213 It is hypothesized the ORP8 may sequester 
Nu62, dismantling the nuclear pore complex, and inhibiting transport to the nucleus.213 
Another interacting partner of ORP8 is sperm associated antigen 5 (SPAG5), a protein 
that binds the mitotic spin and regulates its position, indicating that ORP8 may have a 
role in mitosis.214  
1.6.6 Subfamily-V: ORP9 
Like OSBP, ORP9 can localize between the Golgi and the ER. OSBP 
demonstrated the ability to bind both [3H]25-OHC and [3H]cholesterol, and ORP9 did not 
demonstrate this ability.215 ORP9S has been shown to mimic the function of the yeast 
ORP Kes1p.216 ORP9S is a substrate for PDK2 and overexpression of ORP9L results in 
a reduction of Akt phosphorylation.217 ORP9L mutants that are unable to bind to ER have 
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been shown to localize to large vesicular structures.218 ORP9 is expressed in both long 
and short forms.  ORP9 binds 25-OHC. ORP9 is phosphorylated at S287 by PDK2.  
1.6.7 Subfamily-VI: ORP10 and ORP11 
ORP10 seems to have roles that are involved in lipid metabolism and regulation. 
ORP10 as it associates with microtubules and the Golgi to regulate the secretion of 
apolipoprotein B-100.180 ORP10 has been shown to interact with DIAPH1 as a binding 
partner. DIAPH1 coordinates cellular dynamics by affecting microtubule function.152 
ORP10 has also been shown to dimerizes with ORP9L.180 
ORP11 has been shown to localize with the Golgi and LE. It has also been shown 
to dimerize with the ORP9, which contains an FFAT motif.219  Indicating an intersection 
of signaling where the ER, Golgi, and LE are affected by two ORPs. 
1.7 Ligand Binding to OSBP/ORPs  
1.7.1 Overview 
OSBP was discovered for its ability to bind 25-hydroxycholesterol, and since then 
it has also been shown to bind cholesterol, phospholipids and a wide range of small 
molecule inhibitors.8,19,101,102,192 As previously described, the OSBP/ORP LBD is a large 
domain that can accommodate complex binding to a diverse array of lipids and natural 
products. The [3H]25-hydroxycholesterol ([3H]25-OHC) binding assay that we are using 
is based on a binding assay described by Taylor and Kandutsch.12 This technique measure 
the ability of compounds to bind competitively against tritiated 25-OHC, which uses a 
charcoal-dextran suspension that removes unbound ligand and the remaining protein-
ligand complex is measured through scintillation counting.12  A modification to this assay 
uses TALON resins, to pull down the protein-ligand complex.215,220 Other techniques that 
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have been used to study OSBP/ORP binding include microscale thermophoresis, ELISA, 
and surface plasmon resonance experiments.98,101 
1.7.2 Cholesterol and Oxysterols 
It was observed that cholesterol levels were affected by OSBP levels, but it was 
not initially not believed to be one of its ligands.14,221 Eventually, it was determined 
through His-tagged OSBP, and pull-down experiments that cholesterol is a ligand with a 
KD of 173 nM.
195,222 25-OHC is a common ligand for oxysterol binding studies and have 
been studied extensively with OSBP, possessing the highest affinity of all the oxysterols 
with a KD ranging from 8 to 32nM.
13,19,221,223  
Initially, ORP4L was not observed to bind to 7-KC, 25-OHC or cholesterol 
specifically.17 ORP4L has been shown to bind 25-OHC with a KD ranging from 10nM to 
54nM, and with a KD of 68nM for cholesterol.
19,139,199 The short isoform ORP4S was 
observed to have similar binding constants.139  
ORP1L has been shown to bind both 25-OHC and 22(R)-hydroxycholesterol 
(22(R)-OHC).145  ORP1L was shown to bind 25-OHC with a KD of 97 nM; for ORP1S 
the KD ranges from 84 to 167 nM.
224 It was shown that ORP1S could bind cholesterol 
with a KD of 393 nM.
203 ORP1S has a high-affinity for 22(R)-OHC with a KD of 96 nM.
203  
ORP2 does not have a high-affinity for 25-OHC with a KD of 3.9 µM.
224 However, it does 
show high-affinity for 22(R)-OHC with a KD of 14 nM.
204 ORP2 also binds 7-KC with a 
KD of 160 nM, but there was no specific binding detected with 27-OHC.
204  
The ORP5 LBD has been shown to be able to extract dehydroergosterol in lipid 
exchange assays, indicating an ability to bind sterols.26 No binding assay to determine 
binding constants have been reported for ORP5. The ORP8 LBD was shown to have 
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specific binding to 25-OHC, weak binding to 24(S)-OHC and there was no specific 
binding for 7-KC.27  
Binding constants of ORP9 and its ligands have not been determined. However, 
ORP9L can bind and extract cholesterol from liposomes.215 ORP9S is also able to extract 
fluorescent sterols, cholestatrienol and dehydroergosterol.225 
ORP10 can extract cholesterol from membranes but has not been shown to bind 
oxysterols in vitro.180  There is currently no data on what ligands ORP11 can bind. It was 
shown it was possible to photo-crosslink 25-OHC to ORP3, ORP5, ORP6, and ORP7 
revealing the possibility of using this binding assay with more family members.224 
However, for this type of experiment it is possible that the compound is crosslinking non-
specifically in aliphatic portions of proteins. 
1.7.3 Phospholipids 
The ability to bind phospholipids, especially PIPs, has been observed for many 
OSBP/ORP members. There has only been one reported binding assay that focused on 
phospholipids and OSBP/ORPs. ORP5 and ORP8 LBD PIP ligand binding were studied 
using isothermal titration calorimetry (ITC), and acyl chain truncated water-soluble forms 
of the lipids.31 ORP5 and ORP8 were observed to bind PI3P, PI4P, PI5P, PI(3,4)P, 
PI(3,5)P, PI(4,5)P and PI(3,4,5)P at micromolar levels.31 The remaining studies involve 
lipid exchange assays that give can confirm binding exist but it is difficult to report 
binding constants. OSBP, ORP1, ORP4 has been shown to exchange cholesterol for PI4P 
between two membranes.87,139,201 ORP10S interacts most visibly with PI3P in lipid 
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overlay assays.216 ORP10S, which has no PH domain, has also been observed to extract 
PS in liposomal lipid exchange experiments.38  
1.7.4 ORPphilins and Other Inhibitors 
The ORPphilins are structurally diverse inhibitors that have moderate to high-
affinity for at least two members of the OSBP/ORP proteins (section 1.3.4).19,98  Their 
interactions with the OSBP/ORP proteins have been studied in many ways, one being 
through competitive inhibition of [3H]25-OHC in a charcoal-dextran binding assay with 
results being reported as inhibition constants (Ki). Few have been studied through direct 
binding assays. While some reported constants but have been validated as targeting an 
OSBP/ORP through a series of cellular studies. 
The potent inhibitor OSW-1 binds both OSBP with a Ki of 26 nM and ORP4L 
with a Ki of 54 nM.
19 Cephalostatin 1 is a large steroidal compound that binds OSBP with 
a Ki of 39 nM and binds ORP4L with a Ki of 78 nM.
19 Certain compounds showed marked 
selectivity for OSBP over ORP4L. Ritterazine B binds OSBP with a Ki of 28 nM, but 
with ORP4L it was not possible to establish way complete inhibition constant.19 
Schweinfurthin A is specific for OSBP binding with a Ki of 68nM, ORP4L bound with a 
KD of 2,600 nM
19 It was shown that Schweinfurthin G is also cytotoxic and interact with 
OSBP.98  Immobilized Schweinfurthin G analogs were shown to bind ORP1L and ORPS 
with sub-micromolar affinity via SPR.98  Itraconazole is a purely synthetic triazole 
antifungal has been reported to bind OSBP with a KD of 430 nM using microscale 
thermophoresis.101  Synthetic antiviral compounds T-00127-HEV2 and TTP-8307 also 
target OSBP, but their OSBP binding constants have not been reported.102,103 
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Chapter 2: Profiling Ligand Binding to OSBP and ORP4L with 
Oxysterols and Oxysterol Analogs 
2.1 Abstract 
Human OSBP and ORP4L are closely related members of the OSBP/ORPs, a 
highly conserved lipid-binding protein family found in eukaryotes. Both OSBP and 
ORP4L were found to be targets of a structurally diverse anti-proliferative family as the 
class of natural product compounds known as the ORPphilins. Recent research has 
indicated that selective inhibition of OSBP can be used to treat certain viral infections 
and that inhibiting ORP4L is a potential new route to personalized cancer treatments for 
certain cancers driven by ORP4L expression. Currently, the structure-activity relations 
(SAR) that determine ligand binding affinity and selectivity to the OSBP/ORP family are 
poorly understood. Our research details the profiling of ligand binding to OSBP or 
ORP4L using a diverse library of small molecule ligands, which includes oxysterols and 
oxysterol analogs. The major results of this study show that the position and 
stereochemistry of the hydroxyl on the oxysterol side chain are important to high-affinity 
inhibition binding to both OSBP or ORP4L. We also generated a library of 20-
hydroxycholesterol analogs with various side chains, and the inhibition binding of these 
analogs demonstrates the iso-hexyl side chain found in oxysterols cannot be significantly 
changed without reducing binding affinity. Additionally, saturation of the C5-C6 alkene 
in 25-hydroxycholesterol does not alter OSBP and ORP4L binding affinity. 
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2.2 Introduction  
2.2.1 The Cellular Role of OSBP and ORP4L 
Oxysterol-binding protein (OSBP) and OSBP-related proteins (ORP) subfamily-
I is the most studied and most understood subfamily, which offers the most promising 
drug targets for potential cancer and viral drug development. Subfamily-I is composed of 
oxysterol-binding protein (OSBP), and OSBP-related protein 4L (ORP4L), which shares 
54% sequence similarity to OSBP.5 OSBP and ORP4L also have similar domain 
organizations with N-terminal pleckstrin homology (PH) domains and FFAT motifs that 
direct their subcellular localization upon ligand binding (see chapter 1 section 
1.2.4).139,198,226 Despite their sequence similarities, OSBP and ORP4L, have different 
cellular functions. OSBP exhibits a ubiquitous expression in the tissues. Ligand binding 
to OSBP alters its cellular localization translocating the protein between the trans-Golgi, 
and ER.227 OSBP can exchange cholesterol and phosphatidylinositol-4-phosphate 
between organelles, and this function is exploited by viruses to assist in their 
replication.101 Many viruses, including the Enteroviruses genus of viruses, recruit OSBP 
to their viral replication organelle in order to enrich this organelle with 
cholesterol.101,102,144   
In contrast, ORP4L has a distinct and limited tissue expression pattern in normal 
tissues. ORP4L is not known to affect lipid membrane levels, nor is its localization known 
be changed upon ligand binding. ORP4L is, however, highly expressed in cancer cell 
lines and T-cell acute lymphoblastic leukemia (T-ALL) cells collected from 
patients.133,139,142 ORP4L regulates T-ALL bioenergetics by acting as a scaffold for Gaq/11, 
CD3ε, and PLCβ3, on the plasma membrane resulting in the hydrolysis of 
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phosphatidylinositol-4,5-diphosphate into inositol 1,4,5-trisphosphate (IP3).133 The 
increase in IP3 leads to the release of ER Ca2+ leading to the activation of pyruvate 
dehydrogenase and the downstream initiation of oxidative phosphorylation which 
becomes a major source of energy production in T-ALL.133  
2.2.2 The Therapeutic Potential of Inhibiting OSBP and ORP4L  
The ORPphilins are a class of structurally-diverse anti-proliferative compounds 
that target OSBP and ORP4L (see chapter 1 section 1.3.3).19,228 The ORPphilin 
compounds competitively inhibit binding between tritiated 25-OHC and OSBP or ORP4L 
at nanomolar concentrations.19 Compounds like ritterazine B and schweinfurthin A show 
a significant selectivity for binding OSBP over ORP4L, which indicates that selective 
OSBP and ORP4L binding is possible.19 Itraconazole (ITZ) is a synthetic compound that 
was discovered to exert its antiviral activity by inhibiting OSBP.101  OSW-1 is a steroidal 
saponin natural product that competitively inhibits 25-OHC binding to OSBP and 
ORP4L, at nanomolar levels.19 OSW-1 is known to have potent antiproliferative and 
antiviral properties.2 We hypothesize that it might be possible to synthesize novel OSW-
1 analog compounds that selectively target OSBP or ORP4L, which can then be 
developed as anti-viral or anti-cancer drugs.  
2.2.3 Current Knowledge on the Ligand Binding Capabilities of OSBP and 
ORP4L  
In order to create inhibitors that selectively target OSBP or ORP4L, it is necessary 
to have a thorough understanding of their ligand binding capabilities. The majority of 
OSBP/ORP binding studies have been performed using variations of a [3H]-25-
hydroxycholesterol/charcoal-dextran binding assay.2 Previous binding values reported 
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for OSBP are actually from mouse, hamster and rabbit OSBP, which are conserved with 
human OSBP.13,195,223 Various oxysterols were shown to be competitive ligands in 
radiolabeled 25-OHC binding assays using non-human mammalian OSBP, including in 
the non-purified OSBP enriched fractions. 13,199,223  There are fewer reported binding 
studies for ORP4L.199 There has not been a comprehensive study that screened a library 
of oxysterols for comparison binding to OSBP and ORP4L, which details how 
modifications to an oxysterol affect binding to each subfamily-I member. 
Here we report the first detailed values of human OSBP direct binding values of 
human OSBP to [3H]-25-OHC, using the standard charcoal-dextran binding assay. Using 
this binding assay, we report the first competitive inhibition values of human OSBP to 
OSW-1 and ITZ. Further, we report detailed competitive binding profiles for a diverse 
array of oxysterols and steroidal compounds against OSBP and ORP4L. These results 
show that side chain hydroxyl position and stereochemistry affect competitive binding to 
OSBP and ORP4L. Lastly, we probe the importance of the oxysterol iso-hexyl side chain 
with a series of 20-hydroxycholesterol (20-OHC) analogs.       
2.3 Results and Discussion  
2.3.1 Human OSBP and ORP4L Binds 25-Hydroxycholesterol at Nanomolar 
Levels  
Human OSBP cDNA was cloned into the mammalian expression plasmid. The 
tagless human OSBP (Appendix Figure 23) binds [3H]-25-OHC  with a KD of 22 ± 5 
nM (Figure 9 and Appendix 24), which is consistent with the binding values of prior 
OSBP orthologs that were determined using similar techniques.221,223,229 Competitive 
binding experiments of non-radioactive 25-OHC with the radioactive [3H]-25-OHC 
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compound indicate that the Ki, 25 ± 6 nM, which is similar to the [
3H]-25-OHC OSBP 
KD (Figure 9 and Appendix 25). We observed the same relationship when we studied 
ORP4L, the Ki of  55 ± 8 nM (Figure 9 and Appendix Figure 25 )is consistent with the 
KD of 54 ± 23 nM, which was previously determined.
19  
2.3.2 ORPphilins: OSW1 and Itraconazole Do Not Bind to OSBP or ORP4L in a 
Similar Manner 
Previously, OSW-1 was shown to compete for 25-OHC binding to rabbit OSBP 
and human ORP4L.19 Rabbit and human OSBP have 98% amino acid sequence similarity, 
Figure 9: OSBP and ORP4L Members Bind 25-Hydroxycholesterol at Low 
Nanomolar Levels 
Representative binding curves showing (A) a direct [3H]-25-hydroxycholesterol 
binding assay of Human OSBP (KD of 22 ± 5 nM) showing that 25-
hydroxycholesterol is a high-affinity ligand, and (B) competitive binding assays of 
25-hydroxycholesterol against [3H]-25-hydroxycholesterol with OSBP or ORP4L 
generated Ki values, which matched their reported KD values. (A and B) KD and Ki 
values are mean ± s.d. from at least three independent experiments. 
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and they appear to bind compounds with nearly similar affinities.19,221,222 OSW-1 binds 
human OSBP with a Ki of 9 ± 7 nM, which is slightly lower than the Ki against rabbit 
OSBP of 26 ± 9 nM.19 For ORP4L, OSW-1 has  Ki value of  40 ± 10 nM, which holds 
with the previously determined value of 54 ± 20 nM.19 Overall, these results show that 
OSBP and ORP4L are responding to the binding assay as expected (Figure 10 and 
Appendix Figure 26).   
Previous research shows that ITZ binds directly to OSBP (KD = ~430 nM); 
however, this experiment did not determine if ITZ binds competitively with 25-OHC.101 
Also, ITZ is suspected to be a ligand for ORP4L, but there are no reported binding 
experiments.101  ITZ does not show strong competitive binding with 25-OHC binding in 
OSBP. At best, the binding experiments indicate that ITZ is a low-affinity compound for 
OSBP with a Ki that is greater than 90 µM. Also, ITZ shows no competitive inhibition 
for ORP4L, (Figure 10 and Appendix Figure 27). It was not possible to fully establish 
the bottom of the competition binding curve due to poor solubility of ITZ. Increasing 
concentrations of ITZ beyond 100 M led to an increased error in the binding curves. Our 
binding experiments show a much weaker OSBP Ki than what the previously reported 
OSBP KD.
101 While this result seems contradictory; a possible explanation is that ITZ and 
25-OHC do not bind on the same positions on OSBP. Likewise, while it appears that ITZ 
does not bind ORP4L, the assay only shows that the compound does not inhibit 25-OHC-
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ORP4L binding and it is still possible that ITZ binds ORP4L. 
 
 
Figure 10: OSW-1, but not itraconazole, is a high-affinity competitive inhibitor 
for subfamily-I  
(A) Chemical structure of OSW-1 and itraconazole. Representative binding curves 
showing (B and C) competitive binding assays of OSW-1 or Itraconazole against [3H]-
25-hydroxycholesterol in OSBP or ORP4L shows (B) OSW-1 is a high-affinity ligand 
of both proteins and (C) Itraconazole weakly competes in OSBP and does not compete 
in ORP4L. (B and C) Ki values are mean ± s.d. from at least three independent 
experiments. 
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2.3.3 Oxysterols Reveal hydroxylation and Stereochemistry Affect Competitive 
Binding to OSBP or ORP4L 
The side chain hydroxylation of oxysterols has been indicated as being important 
in the oxysterol binding to OSBP and ORP4L, but side chain hydroxylation has not been 
systematically profiled to determine the structure-activity relation (SAR) of bind to OSBP 
and ORP4L.199,223 To determine the importance of the side chain hydroxyl in interacting 
with OSBP or ORP4L, several oxysterols were tested in the [3H]-25-OHC inhibition 
binding assay which produced inhibition binding constants (Ki values) for each 
compound. The initial oxysterols tested are 20-hydroxycholesterol (20-OHC), 22-
hydroxycholesterol (22-OHC), 24-hydroxycholesterol (24-OHC), and 27-
hydroxycholesterol (27-OHC) (Figure 11). These compounds vary from 25-OHC 
through the position of the hydroxyl group on the side chain; in the case of 24-OHC and 
27-OHC, the hydroxylation position is one carbon removed from the position in 25-OHC. 
When possible, the commercially available stereoisomers of these oxysterols were tested. 
Figure 11: Oxysterol Hydroxylation Substitution Positions  
Each primary oxysterol that was tested had a hydroxyl on one of the numbered 
carbons. The secondary oxysterols had two hydroxyls and are noted with an asterisk 
or an apostrophe.  
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The oxysterols were run in triplicate independent experiments to produce averaged Ki 
values (Table 1).  
The results of inhibition binding experiments to OSBP and ORP4L revealed that 
the positioning and stereochemistry of hydroxylation are important in protein 
interactions. Moreover, minor alterations to side chain hydroxylation dramatically 
impacted each protein.  24(R)-OHC binds OSBP with a Ki of 120 ± 60 nM, which is 
approximately a 4-fold reduction in inhibition binding compared to 25-OHC (see 
Appendix Figure 28). The epimer of 24(R)-OHC, 24(S)-OHC interacts with OSBP with 
a ~2.5-fold higher Ki of 320 ± 80 nM. For ORP4L, the 24(R)-OHC inhibition binding 
curves did not produce interpretable inhibition binding results. The 24(R)-OHC inhibition 
binding results failed to produce a sigmoidal response indicative of single-site inhibition. 
Instead, the curve flattens out in the middle and fails to drop to the minimal level expected 
at high concentrations. However, the 24(S)-OHC inhibition binding curves displayed 
normal sigmoidal inhibition curves with, ORP4L, producing a Ki value of 340 ± 140 nM 
(Table 1 and Appendix Figure 29), which suggest that the abnormal inhibition binding 
Table 1: Observed Ligand Binding Data in OSBP and ORP4L Measured by 
Displacement of [3H]-25-Hydroxycholesterol 
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of 24(R)-OHC to ORP4L is indicative of a more complicated interaction of 24(R)-OHC 
with ORP4L protein.  
In OSBP, the Ki for 25(R),27-OHC is 70 ± 20 nM. However, we report a lower 
interaction for 25(S),27-OHC in OSBP (Ki = 160 ± 70 nM). In ORP4L, 25(S),27-OHC 
appears to be a weak micromolar competitive inhibitor and a Ki value could not be 
determined. Similarly, 25(R),27-OHC did not produce a sigmoidal inhibition curve for 
inhibition binding with ORP4L. Binding curves for 25(R),27-OHC and 25(S),27-OHC to 
OSBP or ORP4L are found in the Appendix (Figure 30 and Figure 31). 
[3H]-22(R)-OHC is a high-affinity ligand for ORP1 and ORP2 (subfamily-II) and 
has been shown to bind OSBP weakly.145,203,204 In the [3H]-25-OHC competitive binding 
assay, 22(R)-OHC  displays low-affinity interactions with an apparent Ki value of >36 
µM for OSBP. There was no indication of interaction between 22(R)-OHC and ORP4L. 
Similarly, 22(S)-OHC produced Ki values of >38 µM for OSBP but did show a higher 
affinity interaction with ORP4L of ~3.4 µM. 22(R)-OHC. These results show that unlike 
the other side hydroxyl positions at C20, C24, C25, and C27, hydroxylation at the C22 is 
not well tolerated for OSBP and ORP4L competitive binding. Binding curves for 22(R)-
OHC and 22(S)-OHC to OSBP or ORP4L are found in the Appendix (Figure 32 and 
Figure 33) 
Unlike 22-OHC, 20(S)-OHC interacts with OSBP with a Ki of 140 ± 30 nM and 
ORP4L with a Ki of 320 ± 90 nM in the binding assay.
67 These results indicate that the 
subfamily-I ligand binding domain (LBD) has an additional hydroxyl binding pocket 
capable of high-affinity interactions with the 20-hydroxyl position, which is consistent 
with crystallographic data from yeast ORP LBD.37 Moreover, 20(S)-OHC has been 
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shown to bind OSBP from other species, but these are the first reported for interactions 
of  20(S)-OHC with human OSBP and ORP4L.17,19,139,199 Binding curves 20(S)-OHC to 
OSBP or ORP4L are found in the Appendix (Figure 34). 
Oxysterols with additional oxidation at positions other than the side chain, such 
as the C7 position of the B-ring, have not been extensively tested for binding to the 
OSBP/ORPs.  Previously published reports indicate that cholesterol and oxysterols that 
have hydroxyls or carbonyl groups at C7 can interact with some OSBP/ORPs.37,196,223 
7α,25-OHC is an oxidized form of 25-OHC that has a hydroxyl at the C-7 position in the 
(S)-configuration. 7α,25-dihydroxycholesterol (7α,25-OHC) interacts with OSBP with a 
Ki of 80 ± 40 nM, and ORP4L bound 7α,25-diOHC with a Ki of 90 ± 60 nM. These 
inhibition binding results are consistent to previously reported results of 7-keto-25-
hydroxycholesterol interacting with mouse OSBP.223 These results indicate that 
substitutions to the C7 position of the B-ring of the oxysterols are accommodated in 
OSBP and ORP4L binding. Binding curves 7α,25-OHC to OSBP or ORP4L are found in 
the Appendix (Figure 35). 
Oxysterols with multiple hydroxyls on the side chain were also tested for 
interactions with OSBP or ORP4L. Testing 20(R),22(R)-dihydroxycholesterol, also 
named Oxy-16, shows that hydroxylation at the C22 detrimentally overrides the positive 
effects of C20 hydroxylation on OSBP or ORP4L interactions. Oxy-16 is a commercially 
available compound that was initially believed to be a Hedgehog antagonist. 20(R),22(R)-
dihydroxycholesterol shows weak binding with  Ki values of 26 µM for OSBP and 3.6 
µM for ORP4L. The binding curves for 20(R),22(R)-dihydroxycholesterol to OSBP or 
ORP4L are found in the Appendix (Figure 36). 5α-hydroxy-6-ketocholesterol 
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(5αOH6KC) is a metabolite formed when cholesterol is exposed to ozone.77 This 
compound is generally found in lung epithelial cells.77 It was determined that 5αOH6KC 
has very weak to no competitive binding against OSBP (Appendix Fig 37). 
Hydroxylation at the C5 and C6 positions does not provide high-affinity OSBP 
interaction; unlike the at other positions that enhance OSBP binding, such as the C25 
position. 19-Hydroxycholesterol is an oxysterol with the hydroxyl on the steroidal core, 
not the side chain. In the [3H]-25-OHC competitive binding assay 19-OHC interferes with 
the binding assay, appearing to be an allosteric enhancer of OSBP. However, the 
increasing radioactivity also appears in experiments with LacZ, which suggest that 19-
OHC is forming micelles that prevent the [3H]-25-OHC from adsorbing to the 
charcoal/dextran (Appendix Figure 38). We cannot determine if 19-OHC is a 
competitive ligand for OSBP.   
2.3.4 20(S)-Hydroxycholesterol and 7α,25-Dihydroxycholesterol Induce OSBP 
Cellular Localization Similar to 25-Hydroxycholesterol 
Upon cellular treatments with established ligands like 25-hydroxycholesterol, 
OSBP has been observed to change cellular localization patterns.19,101,198 Binding a ligand 
alters OSBP localization from a diffuse ER and cytoplasm pattern to strong localization 
near the Golgi.19,101,198 The changes in OSBP localization upon cellular treatment is an 
important confirmation that interactions measured in the in vitro assay also exist in cells. 
Cells were treated with multiple oxysterols, which interact with OSBP in the [3H]-25OHC 
competitive ligand binding assay, to detect any changes in OSBP localization (Figure 
12). For OSBP cellular experiments, 25-OHC is typically dosed at 10 M even though 
the KD for OSBP is ~ 20 nM, which is required due to the compound not being specific 
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for OSBP and to overcome limited cellular uptake from media.19 Moreover, HCT116 
Figure 12: 25-
Hydroxycholestolerol, 
20(S)-
Hydroxycholesterol, and 
7α,25-
Dihydroxycholesterol  
Treatments Induce 
Similar Cellular OSBP 
Localization Patterns 
(A-F) OSBP (green) and 
trans-Golgi (red) were 
visualized in HCT-116 
cells using 
immunofluorescence 
microscopy. Cells were 
treated with vehicle (A), 
10µM 25-OHC (B), 
10µM 20(S)-OHC (C), 
10µM SA-16 (D), 10µM 
24(R)-OHC (E), and 
10µM 7α,25-DiOHC (F) 
for 4 hours and then 
stained using primary 
antibodies for OSBP 
(green) and trans-Golgi 
protein TGN46, followed 
by secondary staining 
with fluorescent 
antibodies. Nuclei (blue) 
were stained with DAPI. 
Scale bars are 10 µm. 
(C&F) 20(S)-OHC and 
7α,25-DiOHC show 
clustering and an increase 
OSBP signal. (D&E) SA-
16 and 24(R)-OHC show 
an increased OSBP signal 
that is more dispersed 
compared to the controls. 
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adenocarcinoma cells treated with 10 µM of either 20(S)-Hydroxycholesterol (OSBP Ki 
= 140 ± 30 nM), sterol analog 16 (SA-16) (OSBP Ki = 890 nM) (see Section 2.3.5, Fig 
14), 24(R)-Hydroxycholesterol (OSBP Ki = 120 ± 60 nM), 7α,25-dihydroxycholesterol 
(OSBP Ki = 80 ± 40 nM), or 25-Hydroxycholesterol (OSBP Ki = 25 ± 6 nM). Compared 
to the ethanol vehicle control, the oxysterol treatments increased the intensity of the 
OSBP fluorescent signal. This effect may be due to ligand binding enhancing the primary 
OSBP-antibody binding to the protein. Previous OSBP imaging reports used different 
antibodies that are not commercially available. The immunofluorescent results indicate 
that 20(S)-OHC, and 7α,25-dihydroxycholesterol cause OSBP to cluster more at the 
Golgi and produces a stronger fluorescence signal, which closely resembles the pattern 
of 25-OHC. In contrast, 24(R)-OHC did not cause a similar localization pattern, despite 
having a similar Ki to 20(S)-OHC. SA-16, which is a compound with the lowest inhibition 
binding to OSBP, did not a strong localization pattern. Repeat micrographs of 20(S)-
OHC, 7α,25-diOHC, 25-OHC are also shown (Appendix Figure 39).   
2.3.5 Structure-Activity Relationship of 20-Hydroxycholesterol Analogs to OSBP 
or ORP4L using the [3H]-25-Hydroxycholesterol Binding Assay  
Determining the structure-activity relationship (SAR) of oxysterol binding to 
OSBP or ORP4L requires compounds with specific structural features designed to probe 
the compound-protein interaction. A small library of compounds based on the 20-OHC 
scaffold was synthesized and tested for interaction to OSBP or ORP4L with the [3H]-25-
OHC competition binding assay. We chose 20-OHC as the parent compound because it 
performs well in the [3H]-25-OHC binding assay with OSBP (Ki of 140 ± 30 nM) and 
ORP4L (Ki = 320 ± 90 nM) making it a reference point for our analogs. Unlike the other 
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high-affinity oxysterols, 20-OHC has its hydroxyl (C20) in the between the steroidal core 
and the isohexyl side chain (Figure 11), which allows us to create 20-OHC analogs that 
have truncated or modified side chains. The 20-OHC analogs made have side chains of 
different length and branching chains (Table 2). The shortest analogs were synthesized 
by reducing and deprotecting pregnenolone acetate (Scheme 1, Figure 13). The 
remaining analogs are accessed with Grignard reactions on the C20-ketone of 
pregnenolone, which allows us to use alkyl magnesium bromide reagents to produce 
compounds that have different hydrocarbon side chains (Scheme 2, Figure 13).  
The sterol analog (SA) compounds were tested for their ability to displace [3H]-
25-hydroxycholesterol (Table 2). SA-7, (R)-pregenolol, and SA-8, (S)-pregenolol, have 
Figure 13: Synthetic Schemes for 20-Hydroxycholesterol Analogs 
Scheme 1: Reduction of pregnenolone acetate with NaBH4 followed by removal of 
the acetate with K2CO3, which produces analogs SA7 (R-epimer) and SA8 (S-
epimer). 
Scheme 2: The acetate is removed, followed by the addition of the alkyl group via 
the Grignard reaction, which produced analogs SA-9 to SA-16  
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a hydrogen atom instead of an isohexyl sidechain and show no competitive binding to 
either OSBP or ORP4L at any concentration below 100 M. The remaining analogs, 
which have alkyl side chains of different lengths, show differing degrees of competitive 
binding to OSBP and ORP4L.  Binding curves for SA-7 and SA-8 to OSBP or ORP4L 
can be found in the Appendix (Figure 40 and Figure 41). SA-9 has an ethyl side chain 
with a C20-(S)-configuration. SA-9 only showed partial competitive binding with 25-
OHC at the highest concentration of 100µM; binding curves are found in the Appendix 
(Figure 42).  SA-10, (R) epimer with an ethyl side chain, was not produced at high 
enough levels to test in the binding assay. SA-11 ((S)-epimer) and SA-12, ((R)-epimer) 
have isobutyl side chains. These compounds show some inhibition binding in the 
micromolar range for OSBP and ORP4L, but the competitive binding was not strong 
enough to fully determine binding constants because the curves failed to bottom out at 
100 µM.  Binding curves for SA-11 and SA-12 to OSBP or ORP4L are found in the 
Appendix (Figure 43 and Figure 44).          
SA-16 possess an isopentyl sidechain, instead of an isohexyl, that is in the (S)-
configuration. Out of all the analogs, SA-16 was the analog with the highest competitive 
affinity to both OSBP and ORP4L. Compared to the Ki values for the parent compound 
20(S)-OHC [OSBP Ki = 140 ± 30 nM; ORP4L Ki = 320 ± 90 nM], SA-16 is a weaker 
competitive inhibitor. However, SA-16 does tend to compete for 25-OHC better in OSBP 
(Ki = 900 nM) than with ORP4L (Ki = 2.0 ± 0.5 µM), the binding curves are found in the 
Appendix (Figure 45).  The yield of SA-17, (R) epimer, was not at high enough levels to 
test in the binding assay. Nonetheless, these experiments show that the presence of the 
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isohexyl sidechain is necessary to have optimal competitive binding to OSBP and 
ORP4L. 
SA-13 ((S)-epimer) and SA-14 ((R)-epimer) have octyl side chains, which make 
them the largest analogs we generated. SA13 and SA14 show partial inhibition binding 
of [3H]-25-OHC at high micromolar concentrations; the lack of complete inhibition 
binding curve over the concentrations tested prevents the generation of Ki values. SA-13, 
the (S)-analog, was indicated to have stronger interactions than SA-14, the (R) analog. 
Binding curves for SA-13 and SA-14 to OSBP or ORP4L can be found in the Appendix 
(Figure 46 and Figure 47).  These results show that a full isohexyl side chain is necessary 
for optimal oxysterol binding and that a long, straight-chain alkyl group disrupts the 
interaction.  
55 
 
  
Table 2: Observed Ligand Binding Data of 20-Hydroxycholesterol 
Analogs (SA-7 to SA-16) in OSBP or ORP4L. Measured by 
Displacement of [3H]-25-Hydroxycholesterol 
56 
 
2.3.6 Screening Non-oxysterol compounds for OSBP or ORP4L via competitive 
inhibition of 25-Hydroxycholesterol Binding 
To identify novel OSBP or ORP4L ligands, we screened eight structurally diverse 
steroidal compounds for inhibition binding in the [3H]-25-OHC competitive binding 
assay (Figure 14). Compound SA-2 is 25-hydroxycholesterol with the C5-C6 alkene 
reduced and a trans relative stereochemistry between the A and B rings. SA-2 has a Ki of 
approximately 28 nM against OSBP, and a Ki of 35 ± 4 nM against ORP4L (Figure 14).  
SA-2 binding curves can be found in the Appendix (Figure 48). This discovery means 
Figure 14: Non-oxysterol Steroidal Compounds Tested in the Competitive 
Binding Assay 
Structurally diverse set of steroidal compounds that were screened against OSBP or 
ORP4L in the competitive [3H]-25-hydroxycholesterol binding assay. SA-2 
demonstrated high-affinity competitive binding. Compounds that were not tested in 
triplicate are noted with an * or **. Ki values are mean ± s.d. from at least three 
independent experiments. 
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that future steroidal compounds that target subfamily-I can use the more stable and 
simplified saturated compounds.  
SA-1 is a steroidal compound with a truncated side chain, a C22-hydroxyl, and a 
C16-C17 alkene in the steroidal D-ring. The SA-1 compound has the potential to be the 
parent compound for novel ORPphilins. SA-1 did not interact with OSBP at any 
concentration tested. For ORP4L, SA-1 began to displace 25-OHC past 10 µM, but only 
partial inhibition was present at 100 M; binding curves can be found in the Appendix 
(Figure 49). SA-1 has features that we have determined to result in weak competitive 
binding to subfamily-I, primarily it has no oxysterol side chain in OSBP and ORP4L 
binding. 21-acetoxypregnenolone was tested but did not show high-affinity binding with 
either protein  (Appendix Figure 50).  SA-1 and SA-2 are the only compounds that were 
synthesized in lab, the remaining compounds in this screen were purchased from 
commercial sources.  
  22-Azacholesterol (22-NHC) is reported to be a strong competitor for 20(S)-
OHC binding in Smoothened in the Hedgehog pathway and screened this compound 
because 20(S)-OHC is high-affinity OSBP/ORP ligand.65 22-NHC shows micromolar 
competitive inhibition of  >100 µM for OSBP and an apparent Ki of 53 µM for ORP4L. 
Binding curves for 22-NHC to OSBP or ORP4L can be found in the Appendix (Figure 
51). The performance of 22-NHC in the binding is one of the few instances where a ligand 
potentially shows specificity for ORP4L over OSBP. Cholesterol is reported to be an 
OSBP and ORP4L ligand, but cholesterol did not show any inhibition binding for [3H]-
25-OHC in our assay, likely due to poor solubility or availability in the binding lysate.195 
The ability of 22-azacholesterol to participate in the [3H]-25-OHC competition binding 
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assays suggests that the incorporation of the presence of the nitrogen at the 22-position 
gives the compound enough polarity to make it soluble in the lysate. The estimated logP 
of 22-NHC is 5.54, and the logP of cholesterol is 7.39. The interaction of 22-NHC with 
ORP4L, although weak, suggests that compounds incorporating nitrogen into oxysterol 
side chain could be used for OSBP/ORP binding.  
U-18666A is a synthetic steroidal compound that induces a cellular phenotype 
similar to Niemen-Pick Type C disease, (Figure 14).230 Multiple OSBP/ORP members 
have been shown to coordinate with the NPC1 protein or are involved in cholesterol 
transport that results in the NPC phenotype.26,161,201,215 For this reason, U-18666A was 
tested to see if could bind OSBP and ORP4L. The compound shows an extremely weak 
to non-existent interaction in experiments with OSBP or ORP4L in the competitive 
binding assay; displacing 25-OHC at 200 µM. Binding curves for U-18666A to OSBP or 
ORP4L can be found in the Appendix (Figure 52). The possibility that U-18666A binds 
other OSBP/ORPs other than OSBP and ORP4L remains, mainly because other 
OSBP/ORPs have been shown to interact with NPC1.26,161,201,215  Moreover, U-18666A 
has some structural similarities to the ORPphilin THEV2, and it is possible to modify U-
18666A to become a more effective ligand. 
Paxilline is a complex steroidal compound with biological effects that are 
unrelated to OSBP/ORP functions. However, paxilline shares some structural similarities 
to the ORPphilin compounds cephalostatin 1 and ritterazine B (Figure 8, Chapter 
1.3.4).231 The similarly between paxilline and the ORPphilins did not extend to ligand 
binding in OSBP or ORP4L. Paxilline competed with 25-OHC binding to OSBP with an 
approximate Ki of >100 µM and ORP4L with an approximate Ki of ~47 µM; the binding 
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assays were done in duplicate because of their low affinity (Appendix Figure 53). Like 
with 22-NHC, this compound seems to be more selective towards ORP4L, but both have 
high Ki micromolar values. 
Ursodeoxycholic acid (UA) is a bile acid produced in nutria, beavers, and bears; 
its structure is an oxidized sterol with a C7 hydroxyl, a propionic acid side chain, and a 
saturated cis A-B ring fusion (Figure 14).232  The results show no competitive binding to 
either OSBP or ORP4L. The absence of binding is best explained by the structure of the 
steroidal core, which is bent due to the cis A-B ring fusion. Like UA, digitoxigenin has a 
cis stereochemistry at the ring fusion. Digitoxigenin also does not show competitive 25-
OHC binding for OSBP in an initial experiment, and it was not tested for interactions 
with ORP4. Binding curves for UA and digitoxigenin can be found in the Appendix 
(Figure 54 and Figure 55).   
Existing structural data on the yeast ORP ligand binding domain reveal that their 
binding pockets that can only accommodate linear compounds like cholesterol and 
ergosterol.21 Assuming that this steroidal binding pocket is similar in the human 
OSBP/ORPs, it would explain why the bent cis-A-B ring fused steroidal compound would 
not be able to bind OSBP or ORP4L.21,35  
2.3 Conclusion  
This study focused on determining the structural activity relations required to 
interact with OSBP and ORP4L in our 25-hydroxycholesterol competitive binding 
experiments.  We studied a variety of oxysterol compounds, including a small library of 
synthetic oxysterols made in the lab. Oxysterols with hydroxyls at C20, C24, C26, and 
C27 show strong interactions with OSBP producing binding curves with low nanomolar 
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Ki values. Oxysterols with hydroxylation at C22 is detrimental to competitive binding in 
both proteins. Oxy-16, the oxysterol which is hydroxylated at C20 and C22, has weak 
micromolar binding, which indicates that adverse effects of C22-hydroxylation override 
the positive effects of C20 hydroxylation. The stereochemistry of the sidechain hydroxyls 
also influenced competitive binding. The most noticeable effect on stereochemistry was 
the failure of the 24(R)-hydroxycholesterol and 25(R),27-hydroxycholesterol epimers to 
show binding to ORP4L, whereas 24(S)-hydroxycholesterol and 25(S),27-
hydroxycholesterol does not produce competitive curves. However, even with OSBP, the 
Ki values were different between isomers.  The synthetic 20-OHC analogs (i.e., SA7-
SA16 compounds) revealed that the entire isohexyl sidechain needs to remain intact to 
have optimal competitive binding.    
The compounds we tested indicate that the structure of the sterol core can affect 
whether a steroidal ligand can bind OSBP or ORP4L. Adding a hydroxyl at C7 is tolerable 
for competitive as was observed with 7α,25-dihydroxycholesterol. Moreover, an 
oxysterol that is reduced at the C5-C6 can still bind if A-B ring core is in the trans-
configuration. The cis-configuration of the fused A-B ring core of a molecule produces a 
bent molecular shape that cannot be accommodated for competitive binding. These 
studies offer valuable information that will guide the design and development of selective 
OSBP/ORP targeting compounds. These results will be especially useful for on-going 
efforts to make new analogs of the OSW-1-compounds that selectively interact with 
OSBP or ORP4L.  
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2.4 Experimental Procedures:  
2.5.1 Materials and Reagents 
[3H]-25-Hydroxycholesterol (25-OHC) was purchased from Perkin-Elmer. All the 
oxysterol compounds were purchased from Cayman Chemical and Sigma-Aldrich. 
Paxilline, U-18666A, and digitoxigenin were purchased from Cayman Chemical. 22-
azacholesterol, 21-acetoxypregnenolone, pregnenolone acetate, and itraconazole were 
purchased from Sigma Aldrich. Norit SA2 charcoal was obtained from Cabot 
Corporation. Pregnenolone acetate and the alkyl halides used to generate the 20-
hydroxycholesterol analogs were purchased from Sigma Aldrich. The OSW-1 compound 
used was obtained through total synthesis in the Burgett lab or from isolation from the natural 
source. 
2.5.2 Plasmids and Cloning  
Human OSBP was obtained in a pOTB7 vector from the Mammalian Gene Collection 
(Thermo Fisher). OSBP was PCR amplified to contain 5’ NheI and 3’ HindIII cut sites. 
The cDNA construct was cloned into the pcDNA 3.1/myc-His (-) C mammalian 
expression vector (Sigma-Aldrich). OSBP was cloned in a manner where OSBP 
expresses without the myc-His tag. The ORP4L construct containing 5’ NheI and 
3’HindIII cut sites was PCR amplified from HCT116 cDNA. The LacZ construct 
containing 5’ NotI and 3’ BamHI cut sites was PCR amplified from K-12 E. coli genomic 
DNA. The completed plasmids were propagated in DH5α E. coli and isolated through 
miniprep and maxiprep kits (Thermo Scientific).  Gene sequences were verified through 
the Oklahoma Medical Research Foundation (OMRF). 
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2.5.3 Tissue Culture 
HEK293T cells were grown in complete Dulbecco's Modified Eagle's Medium (DMEM) 
at 37°C. HCT116 cells were grown in complete McCoy's 5A Medium at 37°C. Cells were 
passaged using TrypLE™ Express Enzyme (ThermoFisher Scientific) for 10 minutes at 
37°C. 
Microscopy  
50,000 HCT116 cells were seeded on glass coverslips in 12 well plates and incubated for 
16 hours at 37°C. The cells were treated with vehicle or 10 µM of a compound and 
incubated for 4 hours at 37°C. The cells were fixed with 4% paraformaldehyde in PBS 
for 10 min. The cells then were washed with ice-cold 1% BSA in PBS 0.1% tween 20 
(BSA/PBST) and permeabilized for 5 min with 0.5% Triton X-100 in PBS. The cells were 
then washed with PBS three times. Then blocked for 30 min at room temperature with 
BSA/PBST. The coverslips were then incubated overnight at 4 °C with a primary 
antibody solution (1:100 Novus Mouse α OSBP1 (1F2) NBP2-00935 and 1:500 for 
Novus Rabbit α TGN46 NBP1-49643) in BSA/PBST. The primary antibody solution was 
removed, and the coverslips were washed three times with 1X PBS. The secondary 
antibody (1:500 Abcam Goat α Mouse 488 and 1:500 Abcam Donkey α Rabbit 594) in 
BSA/PBST was added to the coverslips and incubated at room temperature, for 1 hour, 
in the absences of light. The secondary antibody solution is removed, and the coverslips 
are washed three times with BSA/PBST. The coverslips were additionally washed three 
times with 1X PBS before being soaked in a 300 nM DAPI solution for 10 minutes. The 
coverslips were mounted with Vecta-shield hard mounting media. The slides were 
incubated in the dark, at room temperature, for roughly 24 hours. The slides were stored 
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at -20°C. The images were generated with a Leica SP8 Scanning Confocal Microscope 
using an x63 glycerol/oil immersion objective lens. Imaging was done at the University 
of Oklahoma Samuel Roberts Noble Microscopy Laboratory.  
Transfections and Protein Preparation  
HEK293T cells were seeded at 4x106 in 10 cm2 plates and incubated at 37°C, for 24 
hours. The day of the transfection, a 3 mL solution 24 µg of plasmid, opti-MEM 
(ThermoFisher Scientific), and Lipofectamine 2000 is prepared according to the 
manufacturer’s instructions. The DMEM is removed and gently replaced with the 
transfection solution. The plate is incubated for 4 hours at 37°C. Then 12 mL of antibiotic-
free DMEM is carefully added to the plate and is incubated for 42 hours. The transfection 
media is removed, and the cells are washed with cold PBS. The cells are lysed with 2 mL 
of solution at room temperature for 5 minutes shaking at 250 RPM. The lysis solution is 
composed of M-PER Mammalian Protein Extraction Reagent (ThermoFisher Scientific), 
1x HALT protease inhibitor with EDTA (ThermoFisher Scientific), and 5mM DTT. The 
lysate is then centrifuged for 1 hour at 100,000 g at 4 ºC in a TLA-100.3 rotor (Beckman 
Coulter) in an Optima TLX ultracentrifuge. The protein concentration of the supernatant 
(S100 lysate) was determined using a Bradford assay. The S100 lysate was diluted to 0.2 
mg/mL with binding buffer (50 mM HEPES pH 7.4, 50 mM KCl, 5 mM DTT, 1x HALT 
Protease Inhibitor with EDTA). Due to the high level of expression of OSBP in 
HEK293T, the 0.2 mg/mL OSBP tagless S100 protein lysate was then further diluted 1:4 
with non-transfected HEK293T 0.2 mg/mL S100 lysate. The lysates were aliquoted, 
snap-frozen in liquid N2 and stored at –80 °C until use in the binding assay. When they 
are used, the lysates were quickly thawed on ice, with brief periods of hand warming. 
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2.5.4 [3H]-25-Hydroxycholesterol Charcoal/Dextran Binding Assay 
Preparation of the Charcoal/Dextran (C/D) Suspension  
Successful use of this assay requires careful preparation of the charcoal-dextran to 
remove fine particles. The procedure to prepare the suspension is based on a protocol 
from Taylor and Kandutsch.12 Between washes the charcoal is sedimented by 
centrifugation at 1000 g for 20 min. 1 g Norit SA2 charcoal (Cabott) is added test tube 
15mL falcon tube and washed with 10ml of 1M HCl and followed with a wash of 10ml 
diH20. The charcoal is then washed with 10ml of 5% NaHCO3 and followed with a wash 
of 10ml diH2O. The charcoal is then washed five times with 10ml of 5% Dextran 500,000 
(Spectrum) in 10 mM Tris-HCl buffer, pH 8. The charcoal is then washed twice with 
10ml of 10mM Tris-HCl and 3mM sodium azide buffer, pH 8, and stored at 4°C in 20 ml 
of 10mM Tris-HCl, 3mM sodium azide pH 8 buffer. The night before its use 1g of 
Dextran 500,000 was added to the charcoal and allowed to dissolve overnight.  
Direct Binding Assay 
One direct binding experiment, done with three technical replicates, requires binding 
lysate (~5.5 mL) that is prepared so that in a “V”-shaped 96-well plate, each well contains 
60µL of 0.2 mg/mL S100 lysate, 7.5 µL 20% polyvinyl alcohol (PVA), 5.6 µL 2M KCl, 
0.4 µL binding buffer, the total volume in the well is 73.5 µL. Then 1.5 µL serial dilutions 
in 100% ethanol, starting at 125nM, [3H]-25-Hydroxycholesterol was added to the wells 
using a multichannel pipettor. For non-specific binding interactions, 1.5 µL serial dilution 
[3H]-25-hydroxycholesterol combined 40x 25-hydroxycholesterol is added to an 
additional set of wells on the same plate. The saturation curve required 12 concentration 
points for specific binding and 8 concentration points for non-specific binding. Wells for 
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non-specific binding was not used for LacZ, the negative control. The assay was 
developed in the same way as the competitive assay and is described further down.  
Competitive Binding Assay 
One competitive binding experiment, done with three technical replicates, requires 
binding lysate (~2.8 mL) that is prepared so that in a “V”-shaped 96-well plate, each well 
contains ach well should contain 60µL of 0.2 mg/mL S100 lysate, 7.5 µL 20% PVA, 5.6 
µL 2M aq. KCl, 20nM [3H]-25-hydrocholesterol and binding buffer. The volume of the 
[3H]-25-hydroxycholesterol ligand will vary depending on the stock concentration, the 
total volume in the well should be 73.5 µL. Eleven serial dilutions of the competitive, 
inhibitors that are dissolved in 100% ethanol (Oxysterols) or DMSO (ORPphilins), are 
added to wells using a multichannel pipettor. 25-hydroxycholesterol, the established 
high-affinity ligand, was used as a positive control.    
For both competitive and direct, the assay is incubated for 16 hours at 4°C. Afterward, 60 
µL of the binding lysate mixture was transferred to a new 96-well v-shaped plate 
containing 30 µL of room temperature Charcoal/Dextran. The plate was lightly agitated 
and incubated on a shaker at 250rpm at room temperature for 30 minutes. The plate was 
then spun at 1900xg for 15 minutes at 4°C. Then 30 µL of supernatant was transferred to 
OptiPlates (Perkin Elmer) containing 170 µL of Microscint-20 (Perkin Elmer). The plates 
were sealed with TopSealA-Films (Perkin Elmer). The plate was vortexed at max speed 
for one minute to ensure thorough mixing.  
The data were analyzed with GraphPad Prism 7 using non-linear regression to analyze 
binding curves. Binding curves with R2 values of 0.85 were the cutoff to report values. 
KD and Ki values ± standard deviation were calculated from at least 3 biological 
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replicates. To determine the sampling size, we used a one sample t-test from our results 
(P ≤ 0.1).  
2.5.5 Western Blot  
Overexpressed protein lysate concentration is determined through Bradford assay. 10µg 
of S100 lysate is loaded onto 7.5% or 10% SDS-PAGE gels and electrophoresed at 180 
V for 50 min. Samples were transferred to nitrocellulose (Bio-Rad 1620112) using a 
Trans-Blot® Turbo™ unit at 1.3 A, 25 V for 15 min. The membrane was blocked with 
5% milk protein 1X Tris-buffered saline with 0.2% Tween-20 (TBST) solution for 30 
minutes. The membrane was washed 4 times, 5 min each, with 1X TBST. The membrane 
was incubated overnight at 4°C with a 1:2,000 dilution of mouse anti-OSBP (A-5) 
antibody (Santa Cruz Biotechnology) or a 1:25,000 dilution of a goat anti-myc (NB600-
335) antibody (Novus), each in a 1% milk protein 1X TBST solution. The membrane was 
washed 4 times with 1X TBST.  The membrane was incubated with 1:3000 dilution of a 
goat anti-mouse or a 1:5000 dilution of a donkey anti-goat antibody, each in a 1% milk 
protein 1X TBST solution for 30 minutes at room temperature. The blot is then washed 4 
times with 1X TBST and 1 time with 1X Tris-buffered saline (TBS), 5 min each. The 
blots were incubated in ClarityTM ECL (Bio-Rad 1705061) and imaged on the Bio-Rad 
ChemiDocTM Imaging System using the chemiluminescence setting. Ladder images True 
Blue™ Protein Ladder (Gold Biotechnology) were taken using the colorimetric setting. 
Examples of developed blots with merged ladders for ORP4L-myc-His, LacZ-myc-His 
and OSBP tagless are shown in the Appendix (Fig 23).  
2.5.6 General Method for the Synthesis of 20-Hydroxycholesterol Analogs  
Pregnenolone Acetate Reduction and Deprotection 
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Pregnenolone acetate was reduced with 2 equivalents of NaBH4 and 1 equivalent of CeCl3 
in MeOH/THF.233,234 The acetate protecting group was removed with K2(CO)3, yielding 
SA-7 and SA-8. The compounds were purified using a Luna 5µm C8(2) 100Ǻ 
Phenomenex semi-prep column, with different MeCN/0.1% formic acid in H2O gradient 
in an LCMS-2020 system (Shimadzu). The structure of pregnenolone acetate and the 
purified products were determined through NMR and are shown in the Appendix (Fig 56, 
Appendix Fig 57, and Appendix Fig 58).   
Grignard Reaction 
The remaining analogs were synthesized with the Grignard reaction. Alkyl halides were 
reacted with magnesium metal to create Grignard reagents, which were then used to attack 
pregnenolone acetate. The acetate protecting group was removed with K2(CO)3, yielding 
the remaining analogs. The compounds were purified and isolated with an LCMS-2020 
system (Shimadzu). The compounds were purified using a Luna 5µm C8(2) 100Ǻ 
Phenomenex semi-prep column, with different MeCN/0.1% formic acid in H2O gradient 
in an LCMS-2020 system (Shimadzu). The purified products were verified through NMR. 
  
68 
 
Chapter 3: Developing A Systematic Biochemical Approach to Study 
Ligand Binding to OSBP 
Juan Nuñez*, Anh Le*, Paul Sims*, Naga Rama Kothapalli *, and Anthony Burgett* 
*Department of Chemistry and Biochemistry, University of Oklahoma, 101 Stephenson 
Pkwy, Norman, Oklahoma, 73019, United States  
 
Juan Nuñez was responsible for writing this chapter. He was responsible for all 
experiments and data analysis for this chapter, unless otherwise specified. Juan mentored 
undergraduates, Ms. Bliss Baird (OU F.Y.R.E), Ms. Courtney Martin (OU F.Y.R.E), and 
Mr. Matthew Finneran (OU Structural Biology R.E.U), in molecular biology to clone 
ORP genes into the mammalian expression vectors. Dr. Naga Rama Kothapalli mentored 
and assisted in protein purification. Dr. Paul Sims donated the Sephadex column and 
carried out the Ammonium Sulfate precipitation. 
 
 
 
 
 
 
 
 
69 
 
Chapter 3: Developing A Systematic Biochemical Approach to Study 
Ligand Binding to OSBP 
3.1 Abstract  
Oxysterol-binding protein (OSBP) is a lipid binding protein with a conserved ~50 
kDa C-terminal ligand binding domain (LBD). The LBD can bind to an array of 
structurally-diverse lipid ligands including oxysterols and phospholipids. In cells, OSBP 
is reported to counter transport cholesterol and phosphatidylinositol-4-phosphate (PI4P) 
between the ER and Golgi membranes. Recently, OSBP was determined to be essential 
for the replication of a range of human pathogenic viruses. The ORPphilin compound 
OSW-1 is a complex steroidal compound fused with a disaccharide moiety that has anti-
viral and anti-proliferative abilities. The anti-viral properties of OSW-1 are caused by 
inhibiting OSBP. OSW-1 binds to OSBP with a high-affinity (OSW-1 Ki = 9 ± 7 nM), 
which is measured through competitive inhibition binding assays with a tritiated 25-
hydroxycholesterol (25-OHC), a known high-affinity OSBP ligand. The protein structure 
of human OSBP or OSBP-related proteins (ORPs) have not been determined, and 
therefore, there is limited information on how the OSW-1-compound interacts with OSBP 
on the molecular level. An understanding of the structure-activity relations (SAR) of 
OSBP and the OSW-1-compound interaction would allow for the design of improved 
OSW-1 analog compounds for potential anti-viral drug development. To better 
understand this interaction, a model of the OSW-1 compound binding to OSBP was 
generated to a diagram which key residues that are essential in OSW-1-OSBP 
interactions. We hypothesize that the structure of OSW-1 mimics both the steroidal and 
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PI4P binding to OSBP simultaneously. A series of OSBP residues important for 
interacting with the OSW-1, but not binding 25-OHC, were identified and mutated. The 
selected residues are thought to be important in mediating the contact between ORP 
proteins and PIPs. One OSBP mutant, OSBP H522A, was successfully tested in ligand 
binding assays, and the H522A mutant showed substantially reduced interactions with 
the OSW-1 compound supporting our model. Additionally, the SAR of OSW-1 and 
OSBP was further explored through the testing for binding interaction of a series of OSW-
1-derived compounds to OSBP. Further, progress in the purification of overexpressed 
OSBP is detailed.  
3.2 Introduction  
3.2.1 The OSBP/ORP Ligand Binding Domain 
The molecular level interactions of oxysterol binding protein (OSBP), and the 
OSBP-related proteins (ORPs), with ORPphilins, are not understood, but it is likely that 
they bind at the ligand binding domain (LBD). The OSBP/ORP LBD is the most common 
domain of this protein family.21 The LBD is a large domain that can bind different type 
oxysterols and some phospholipids.21 Unfortunately, there is no structural data for the 
human OSBP/ORPs. However, there is structural data for a few yeast OSBP/ORPs, 
including structures with bound ligands that are established ligands for the human 
OSBP/ORPs.2,21 The structural data that is most relevant to OSBP is of yeast ORPs bound 
to 25-OHC or phosphoinositide-4-phosphate (PI4P).21 In mammalian cells, OSBP 
counter transports cholesterol and PI4P between the ER and Golgi membranes; this lipid 
transport function between organelle is believed to be hijacked during viral replication to 
control lipid levels in viral replication organelles.87,101,192 In experiments with OSBP, 
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OSW-1 competitively inhibits the 25-hydroxycholesterol in binding assays and inhibits 
the exchange of sterols and PI4P between membranes in lipid exchange experiments.19,87 
(A) Crystal structures of Osh4 LBD (green) bound to 25-hydroxycholesterol (PDB: 
1ZHX)37 and Osh4 LBD (blue) bound to PI4P (PDB: 3SPW).40 (C) Molecular 
interaction diagrams of 25-OHC (PDB: 1ZHX) 37 or PI4P (PDB: 3SPW) 40 the Osh4 
ligand binding pocket. (A and B) Each ligand occupies similar regions of the domain, 
but form hydrogen bonds with different residues. (A) Molecular graphics were 
generated with UCSF Chimera. (C) Interaction diagrams were generated with 
LigPlot+. 
Figure 15: 25-OHC and PI4P Binding Pocket of Ligand Binding Domain of Osh4 
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These experiments suggest that OSW-1 inhibits both the binding interactions of sterols 
and PIPs.  
Currently, there are only four yeast ORP LBD structures that have been solved: 
Osh1, Osh3, Osh4 and Osh6.21 The Osh3 LBD is closest to OSBP in amino acid sequence 
similarity, but it can only bind phospholipids making it challenging to model the steroidal 
OSW-1.39 However, Osh4 can bind both PI4P and various sterols, and it can exchange 
cholesterol for PI4P in liposomal lipid exchange experiments.37,40,42 In particular, Osh4  
has been crystallized with 25-OHC (PDB: 1ZHX) and Osh4 with PI4P (PDB: 3SPW) 
(Figure 15). 37,40 In Osh4, 25-OHC, and PI4P occupy the same hydrophobic regions of 
the ligand binding domain, but these molecules use different residues to form hydrogen 
bonds (Figure 15). Moreover, the residues that form stabilizing interactions with PI4P 
are conserved in both yeast and human LBDs.21 Studies have shown that it is possible to 
generate OSBP mutants that have some of these highly conserved basic residues (H522, 
H523, and K524) replaced with alanine residues, which remove the ability of the mutant 
OSBP to extract PI4P from membranes but preserves their ability to extract sterols, in 
lipid exchange assays.87,192 However, these OSBP mutants have not been tested for direct 
OSW-1 or 25-OHC binding.139,235  
3.2.2 Structure of OSW-1 
OSW-1 is a steroidal saponin natural product with potent antiproliferative and 
antiviral properties, which exhibits its cytotoxic effects by inhibiting OSBP function.19,86 
OSW-1 has an aglycone consisting of an oxidized sterol connected through the C16-
hydroxyl to a para-methoxybenzoate-containing disaccharide moiety.79 Since
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, 
(A) Simplified diagram of an OSBP/ORP LBD bound to an oxysterol or PI4P (B) 
2D molecular interaction the Osh4 binding pocket (PDB: 3SPW)40 with OSW-1 
replacing PI4P, showing potential residues that can interact with OSW-1. The 
interaction diagram was generated with LigPlot+, using (PDB: 3SPW) 40 and the 
PI4P was replaced with a 2D structure of OSW-1 (ChemDraw). 
 
Figure 16: Hypothetical OSW-1 Interaction 
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OSW-1 has a steroidal core it is expected that part of the molecule occupies the lipophilic 
portion of the LBD that is normally occupied by 25-OHC or the acyl chains of PI4P 
(Figure 16). However, it is uncertain where the disaccharide moiety and the para-
methoxybenzoate are placed during binding.  
It is possible that the isohexyl side chain and the arabinose-xylose moiety have 
torsional freedom that could allow OSW-1 to adopt conformations that could allow it to 
occupy regions of the binding pocket that PI4P would typically occupy. More specifically 
OSW-1 could interact with both the oxysterol binding pocket and with the residues 
conserved for PI4P binding (Figure 16). It is possible to use mutations to determine 
important amino acid residues that affect OSW-1 binding that will not affect binding to 
25-hydroxycholesterol (25-OHC). Through these experiments, we can develop detailed 
diagrams that establish which residues are essential in the OSW-1-OSBP interaction 
(Figure 16). Also, OSW-1 has two hydroxyls on the xylose part of the disaccharide 
moiety that is not required for high-affinity binding, which can be useful to produce 
fluorescent compounds.19 However, these functional groups also beg the question of how 
OSW-1 is interacting with OSBP. OSW-1 is a complex, flexible molecule that can adopt 
many conformations to bind the pocket, and these mutations will allow us to begin to 
understand this type of interaction OSW-1 and OSBP have.   
3.3 Results and Discussion    
3.3.1 Site-Directed Mutagenesis of OSB 
The five residues targeted for OSBP mutation are methionine 436, lysine 493, 
asparagine 496, histidine 522, and lysine 736. These residues are conserved in all 
OSBP/ORP proteins and are likely to form interactions with OSW-1 (Figure 16). In the 
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yeast structures, the residues that correspond to methionine 436 are not involved in direct 
ligand binding interactions.37,38,40 However, the amide in the backbone of these residues 
form hydrogen bonds with the polar head group of PI4P, and by changing this residue to 
proline, the backbone hydrogen bond donor should be removed.37,38,40 OSBP residues 
K493 and N493 are conserved to the yeast residues that form part of the end of the central 
alpha-helix, and these residues hydrogen bond to the 1-phosphate of PI4P.38–40 OSBP 
H522A is in the “fingerprint” of the ligand binding domain and is the most conserved 
histidine among the other ORPs.63 The yeast histidines in the fingerprint region are used 
to form direct hydrogen bonds with the 4-phosphate in PI4P.39,40In Osh3 and Osh4, this 
histidine is involved in forming direct hydrogen bonds with the inositol sugar (Osh3) or 
Figure 17: Gene Blast of OSBP Mutants and Western Blot of OSBP 
Mutants 
Sequence alignment of mutant OSBP against wild-type OSBP, showing a change 
from CAT to GCT (OSBP H522A), and ATG to CCG (OSBP M436P). The 
western image is of ORP4L-myc-His, OSBP H522A-myc-His, and OSBP M436P-
myc-His, transferred from a 7.5% SDS PAGE gel. The image was developed with 
primary anti-myc antibody, and HRP conjugated secondary antibody. The ladder 
is Precision Plus Protein™ Dual Color Standard (Bio-Rad). 
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the 4-phosphate group (Osh4).39,40 In yeast, residues conserved with OSBP K736 are used 
to form hydrogen bonds directly with the phosphoinositol head group.39 
To create the OSBP binding mutants we used human OSBP as a template for site-
directed mutagenesis. The primers were designed using the specifications from the 
QuikChange II Site-Directed Mutagenesis kit (Agilent). OSBP is a relatively large (2.4 
Kb) GC-rich gene, which makes it challenging to work with when it comes to molecular 
biology. Out of the initial planned site-directed mutagenesis reactions, two successful 
mutants were generated, OSBP M436P and OSBP H522A (Figure 17). Fortunately, 
OSBP H522A expresses at a high enough level to be used in the binding assay.  
3.3.2 Binding Profile of OSBP H522A 
OSBP H522A can bind [3H]-25-OHC with a KD value of 12 nM. Using cold 25-
OHC as a direct competitor for [3H]-25-OHC, OSBP H522A produced a Ki of 53 nM. 
These results indicate the H522A is unchanged from the wild-type OSBP binding 25-
OHC in the in vitro assay, which supports our proposed model. With the condition of low 
nanomolar binding to 25-OHC being met, it is possible to test the mutant for inhibition 
binding to the OSW-1 compound. Binding 25-OHC is an essential requirement to 
continue this experiment and is consistent with the structural data in Osh4. 
OSW-1 produced a Ki value of 18 nM against wild-type OSBP-myc-His, which 
is consistent with previously established values for our OSBP experiments and with 
literature values (Figure 18).19 However, OSBP H522A displayed a substantially weaker 
competitive binding affinity with an apparent Ki = 400 nM. The OSW-1 inhibition 
binding graph will require additional high concentration points to produce a bottom 
77 
 
typical of these binding curves.  These initial results suggest the H522A mutation is 
substantially reducing OSW-1 binding while not affecting 25-OHC (Figure 18). 
Figure 18: Binding Assays of OSBPH522A and wild-type OSBP 
 (A and B) Direct [3H]-25-hydroxycholesterol binding assay of (A) OSBP H522A, 
(B) and LacZ as a negative control. (C-F) Competitive [3H]- 25-hydroxycholesterol 
binding assays with 25-hydroxycholesterol or OSW-1. (A and C) OSBP H522A 
binds 25-hydroxycholesterol with a high-affinity (apparent KD = 12nM and apparent 
Ki = 53nM. (D and F) Wild-type OSBP competitive ligands with high-affinity 25-
hydroxycholesterol (apparent Ki = 23nM) or OSW-1 (apparent Ki =18 nM) (E) 
OSBP H522A binds OSW-1 with a decreased competitive affinity (apparent Ki = 
400 nM). 
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3.3.3 Binding Assay of OSW-1 Analogs 
Initially, OSW-1 analogs were used to discover that OSBP and ORP4L were the 
targets of the ORPphilins.19 OSW-1 derived compounds produced by adding an aromatic 
amine linker to the compound were tested for interactions with OSBP and ORP4L 
(Figure 18). These analogs, especially the free amine analogs OA-2 and OA-3, can be 
further developed into new OSW-1 analogs, including possibly fluorescent OSW-1 
analogs. OA-2, OA-3, and OA-5 were produced in the Burgett research group by Dr. Anh 
Le and other organic chemists. In compound OA-5, the amine is protected as part of the 
Alloc protecting group. OA-5 was previously reported to bind OSBP with low Ki values 
Figure 19: OSW-1 Analogs and Apparent Competitive Binding to OSBP 
(A) Chemical structure of OSW-1, OA-2, OA-3 and OA-5. (B-D) Competitive 
[3H]-25-hydroxycholesterol binding assays with (B) OA-2, (C) OA-3, and (D) 
OA-5. (B) OA-2 is the weakest competitive inhibitor (apparent Ki = 100) (C and 
D) OA-3 (apparent Ki = 33 nM) and OA-5 (apparent Ki = 30 nM) are a similar 
high binding affinity. 
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in the [3H]-25-OHC competitive binding assay, but the OA-2 and OA-3 compounds have 
never been evaluated for OSBP interaction.19 The free amine OSW-1 analog OA-3 retains 
a low apparent Ki value identical to OSW-1 for OSBP. OA-2 exhibits weaker apparent 
binding interactions, which is consistent with previous indications of substituents on the 
4-xylose hydroxyl.19  These results show that OSW-1-amine analogs interact with OSBP 
identical to the OSW-1-compound, and these compounds can be used to install a 
fluorophore for additional OSW-1 cellular experiments.19  
3.3.4 Purification of Overexpressed OSBP 
Currently, there are no successful methods to produce purified and fully 
functional overexpressed OSBP protein. Access to pure OSBP would allow for extensive 
biochemical and structural characterization of OSBP. We purified tagless OSBP using 
ammonium sulfate precipitation combined with size exclusion chromatography (SEC). 
The tagless OSBP protein expresses at much higher levels in HEK293T cells than the 
myc-His-tagged protein. After the ammonium sulfate precipitation and resuspension, the 
samples were split and purified by two different columns: a Sephadex column (courtesy 
of Dr. Paul Sims), the beads (Sigma-Aldrich) were reconstituted in 10mM Tris buffer and 
hand-poured into a column for gravity filtration, and an ENrich™ SEC 650 column (Bio-
Rad) for HPLC purification. All fractions, including those collected before 
chromatography, were assayed for binding of 25 nM of [3H]-25OHC (Table 3). The 
binding results show that the Sephadex Column Fractions 6 and 8, and SEC Column 
Fraction 1 were the most enriched for 25-OHC binding activity, which is indicative of 
OSBP enrichment. Additionally, the 25-OHC binding activity is also evidence of that the 
partially purified OSBP is functional. Interestingly, the purified fractions were stored at 
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4°C for several weeks before testing. This long-term stability of ammonium sulfate 
Table 3: OSBP Tagless Purification Table Ammonium sulfate 
precipitation followed by size exclusion chromatography 
(Sephadex column or SEC 650 column), tested for apparent 
binding of [3H]-25-Hydroxycholesterol  
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enriched OSBP is much different from the stability of overexpressed OSBP in the lysate. 
OSBP lysate from mammalian cells must be snap frozen, stored at -80°C, and quickly 
thawed when used to preserve 25-OHC binding activity.   
Affinity chromatography of OSBP-myc-His-tagged protein was also attempted. 
The OSBP-myc-His was transfected and overexpressed in HEK293T cells with the 
established protocols, and then overexpressed lysate was absorbed to a nickel resin. 
Fractions were eluted off the nickel resin using increasing concentrations of imidazole. A 
10% SDS-PAGE with a colloidal Coomassie stain identified the fractions that possessed 
the eluted purified OSBP-myc-His protein (Figure 20). This method produces highly 
Figure 20: Colloidal Coomassie Stain of OSBP-Myc-His Fractions in a 10% SDS-
PAGE Gel 
Ni-NTA column purified OSBP-Myc-His fractions in a 10% SDS-PAGE gel stained 
overnight with colloidal Coomassie. Crude is lysate from HEK293T overexpressing 
OSBP-myc-His. Fractions 16 and 15 are the most purified compared and appear to be 
enriched with OSBP. The ladder is Precision Plus Protein™ Unstained Standard (Bio-
Rad) 
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enriched OSBP fractions, and the method could form the basis for large-scale purification 
of OSBP.  
3.3.5 Obtaining OSBP/ORP Plasmids 
 To further establish a detailed understanding of OSBP/ORP ligand binding, 
additional, a representative member of each OSBP/ORP subfamily was cloned in order 
to evaluate ligand binding. ORP cDNAs, isolated from HCT-116 cells, were PCR 
amplified and cloned into pcDNA™ 3.1/myc-His(-) C. The current ORPs that have been 
cloned from HCT-116 cDNA are ORP2, ORP3, ORP5, and ORP11. ORP1, ORP9, 
ORP10, ORP1A in pcDNA™4/HisMax A were given to us by Dr. Vesa Olkkonen. ORP9 
was kept pcDNA™4/HisMax A because it does not have restriction sites that are 
compatible with pcDNA™3.1/myc-His(-)C. Future research will express and evaluate 
these ORP proteins for ligand binding. 
3.4 Conclusion   
The information, procedures, and tools developed in this chapter will allow us to 
design and test novel OSW-1 analogs. The initial results indicate that OSW-1 requires 
residues that are needed for PI4P binding in order to exert strong competitive binding. 
These experiments suggest that OSW-1, and possibly other ORPphilins, acts as a hybrid 
PI4P-cholesterol ligand for OSBP. More experimentation will need to be done to 
determine exact details that impart high-affinity.  
Purifying expressed mammalian OSBP/ORPs is currently an unmet research 
need. Ammonium sulfate precipitation of tagless OSBP combined with size-exclusion 
chromatography produces highly enriched functional OSBP. The ammonium sulfate 
enriched OSBP fractions are very stable stored at 4°C. Affinity chromatography of His-
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tagged OSBP produces enriched OSBP in fewer steps than ammonium precipitation. 
Future research in the lab will build on these purification efforts to develop methods to 
produce pure OSBP and other OSBP/ORPs on experimentally useful scales.  
3.5 Experimental Procedures  
3.5.1 Materials and Reagents 
[3H]-25-Hydroxycholesterol was purchased from Perkin-Elmer. 25-hydroxycholesterol 
was purchased from Cayman Chemical Company. Norit SA2 charcoal was obtained from 
Cabot Corporation. QuikChange II, Site-Directed Mutagenesis kit, was ordered from 
Agilent Technologies. Primers were ordered from Sigma-Aldrich. The OSW-1 and OA 
compounds compound used were obtained through total synthesis in the Burgett lab or from 
isolation (OSW-1) from the natural source. 
3.5.2 Plasmids and Mutations  
Human OSBP in pcDNA™ 3.1/myc-His(-) C mammalian expression vector (Sigma-
Aldrich) was used as the template for site-directed mutagenesis. Primers were designed 
using the specifications from the QuikChange II Site-Directed Mutagenesis kit (Agilent), 
Forward Primer Name Primer 5' to 3' 
FO_M436P GAACTCTCTAAGATCCCCCCGCCGGTAAACTTTAATGAG
FO_K493A GTCTTCCGCACCAGTGCGCCATTCAACCCACTG
FO_N496A ACCAGTAAGCCATTCGCCCCACTGCTTGGGGAG
FO_H522A CTCTGTGAACAGGTGAGTGCTCATCCCCCTGCTGCTGCG
FO_K736A GAAGCAAATGCGGAGGCGCAGCGCCTGGAGGAA
Reverse Primer Name Primer 5' to 3' 
RO_M436P CTCATTAAAGTTTACCGGCGGGGGGATCTTAGAGAGTTC
RO_K493A CAGTGGGTTGAATGGCGCACTGGTGCGGAAGAC
RO_N496A CTCCCCAAGCAGTGGGGCGAATGGCTTACTGGT
RO_H522A CGCAGCAGCAGGGGGATGAGCACTCACCTGTTCACAGAG
RO_K736A TTCCTCCAGGCGCTGCGCCTCCGCATTTGCTTC
Table 4: OSBP Site-Directed Mutagenesis Primers 
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Table 4. The PCR and transformation were followed as directed by the QuikChange II 
manual. Colonies were selected, grown in LB-Amp broth, then the plasmid was extracted, 
and the presence of the mutation was verified through the Oklahoma Medical Research 
Foundation (OMRF). 
3.5.3 Tissue Culture 
HEK293T cells were grown in complete Dulbecco's Modified Eagle's Medium (DMEM) 
at 37°C. Cells were passaged using TrypLE™ Express Enzyme (ThermoFisher 
Scientific) for 10 minutes at 37°C. Cells are seeded at 4X106 in 10 cm2 plates and 
transfected with 24 µg of plasmid after 24 hrs. 
3.5.4 Charcoal/Dextran Binding Assay 
The [3H]-hydroxycholesterol charcoal/dextran binding assay is the same as in chapter 2.   
3.5.5 Protein Purification 
Size Exclusion Chromatography 
OSBP pcDNA™3.1/myc-His(-) C (Tagless) was transfected into HEK293T. After 48 
hours, the cells were lysed using MPER/HALT and centrifuged at 100,000 xg, for 1 hour 
at 4°C. The supernatant was precipitated with the gradual addition of solid ammonium 
sulfate until the lysate reached 50% saturation.  The resulting precipitate was resuspended 
in a 10mM Tris HCl buffer pH 7.4. Size exclusion chromatography was done through a 
Sephadex column or Bio-Rad NGC™ Medium-Pressure Liquid Chromatography System 
with Enrich SEC650, 10/300 mm, column. All fractions were stored at 4°C and were 
tested for apparent binding.  
Nickel Affinity Chromatography 
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HEK293T cells were transfected with L OSBP pcDNA™3.1/myc-His(-) C (Tagless). The 
cells were lysed, at 48 hours, using MPER/HALT (with no DTT) and centrifuged at 
100,000xg at 4°C. The sample was purified using a Bio-Rad NGC™ Medium-Pressure 
Liquid Chromatography System. The loading buffer is 150 mM monopotassium phosphate, 
150 mM KCl, 10 mM imidazole, pH 8. The elution buffer is150 mM monopotassium 
phosphate, 150 mM KCl, 500 mM imidazole, pH 8. The system was using a Nuvia IMAC 
Ni-charged, 5 mL, column at 4°C. The samples were collected under 1.0 mL/min flow 
rate in 1.0mL fraction size, with a total of 12 fractions from the elution step. 
3.5.6 Western Blot  
The Western blot protocol is the same as in chapter 2. 
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Chapter 4: Conclusion and Future Outlook  
The research presented in this dissertation is designed to study the ligand binding 
capabilities of oxysterol-binding protein (OSBP) and OSBP-related protein (ORP) 
subfamily-I, namely OSBP and ORP4L. The first chapter focused primarily on the sterol-
binding capabilities of human OSBP and ORP4L. We chose to use human OSBP for our 
binding profiles to avoid any potential species-specific effects from studying non-human 
OSBPs. The initial results with human OSBP reveal that this protein binds 25-
hydroxycholesterol and OSW-1 with a similar affinity to the rabbit OSBP.19 Through the 
oxysterol binding profiles, we identified structure-activity relations (SAR) for the 
interaction of oxysterols with OSBP or ORP4L.  
The position of the hydroxyl on the steroidal side chain is essential for strong 
interactions with OSBP and ORP4L, as determined using the [3H]-25-hydroxycholesterol 
competitive binding assay. Specifically, high-affinity interaction with OSBP or ORP4L 
were observed with hydroxylation at C20, C24, and C27, but not C22. The 22-OHC 
oxysterols show weak interactions with OSBP or ORP4L. Hydroxylation at C22 
negatively interacts with both OSBP and ORP4L, based on the weak binding of the 
20(R),22(R)-dihydroxycholesterol compound. The weak interaction of 22-OHC with 
OSBP and ORP4L is especially interesting since the OSW-1 structure has a C22 carbonyl. 
It is possible a C22 carbonyl does not negatively interact with OSBP the same way a 
hydroxyl does, or OSW-1 might not perfectly overlap in the same binding pocket as 22-
OHC. Previous pharmacological studies with OSW-1 have questioned the importance of 
the presence of this carbonyl.79 
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The results also indicate that stereochemistry of side chain hydroxylation 
influences competitive binding to the OSBP and ORP4L. The (R)-configuration of 24-
hydroxycholesterol and 27-hydroxycholesterol did not show strong competitive binding 
compared to the (S)-configuration in ORP4L. For OSBP, the (R) epimers of these 
oxysterols did bind with nanomolar competitive affinities. OSBP also tends to bind (S) 
epimers of 24-hydroxycholesterol and 27-hydroxycholesterol with slightly weaker 
binding affinities than the (R). It is evident that the configuration of the molecule 
influences how it binds to these proteins. OWS-1 is a steroidal compound, the information 
we have developed can allow us to generate OSW-1 analogs with modified steroidal 
features of that can potentially target a single member of the OSBP/ORP family.  
To better probe the role of the oxysterol side chain on the SAR of OSBP and 
ORP4L binding, we made a library of 20-hydroxycholesterol analogs with various side 
chains. 20(S)-hydroxycholesterol can be used as to establish as a baseline for our 
experiments. The 20-OHC analogs we generated never reached the same degree of 
competitive binding affinity as the parent compound. Our results show that the 
compounds that are binding in the steroidal ligand binding domain require either a side 
chain or something identical to the isohexyl side chain found on cholesterol. These results 
also carry implications for future analogs of OSW-1, which possess the isohexyl side 
chain, although the C22 of the side chain is oxidized to the ketone. Future OSW-1 analogs 
will likely require the same or a minimally altered isohexyl side chain. Other studies have 
indicated that the iso-hexyl acyl chain is not necessary for the pharmacological activity 
of the OSW-1 compound.79  
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Chapter Three focuses on biochemical properties of human OSBP and ways to 
use these properties to study ligand binding. Our goal is to develop a detailed 
understanding of how ORPphilins are binding in the OSBP/ORP ligand binding pocket, 
specifically OSW-1 with OSBP (see Chapter 3 Figure 16). We began mutational studies 
that are based on the highly conserved residues that interact with phosphoinositide-4-
phosphate in yeast ORP crystal structures. These studies are the first to suggest that the 
OSW-1 compound’s high-affinity binding relies on, at least, one residue (histidine 522) 
that is also used to interact with PI4P. Testing more residues more will lead to detailed 
interaction diagrams (see Chapter 3 Figure 16B), which will then allow us to generate a 
stronger model and design more effective OSW-1 analogs.  
In chapter three, we also investigate parameters that will allow us to test 
OSBP/ORP ligand binding further. Through our efforts to purify overexpressed OSBP 
with ammonium sulfate, we found that OSBP enriched fractions were more stable under 
refrigeration conditions than unfractionated OSBP lysate. We also produced apparent Ki 
values for OSW-1 analogs that have the potential to be further developed as novel probe 
analogs, including the fluorescent analogs. The fluorescent OSW-1 could be used to 
develop a direct OSW-1 binding assay for the OSBP/ORPs, which would allow for an 
OSW-1 KD to OSBP or ORP4L to be determined for the first time.  
This dissertation lays the groundwork to build the next generation of OSW-1 
based ORPphilin compounds that can be potentially used as chemical probes for research 
and drug development lead compounds.  The OSW-1 compound induces many interesting 
cellular effects through targeting OSBP and ORP4L that other OSBP/ORP ligands, such 
as 25-OHC, fail to cause.19 The unique activity of OSW-1 might be explained by it 
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simultaneously mimicking both the sterol and PI4P when bound to OSBP. This may lock 
the OSBP protein in a unique state, stopping the exchange of lipids between membranes, 
and triggering OSBP degradation and Golgi disruption. It is possible that cell initiates the 
destruction of the Golgi and causes the proteasomal degradation of this “OSW-1 locked” 
OSBP.  
The cytotoxic activity of OSW-1 likely involves targeting ORP4L instead of 
OSBP; this is based on the result that that RNAi silencing of OSBP does not affect cell 
proliferation and survival.139 ORP4L is needed for cell survival and also affects Golgi 
morphology.22,133,139 However, ritterazine B, and schweinfurthin A are cytotoxic 
compounds that bind ORP4L with substantially reduces affinity, as measured by Ki, than 
OSBP. 19 All of these results further emphasize the need to study the ligand binding 
capabilities of the remaining ORPs, especially with the ORPphilins.  
OSBP and ORP4L, and to a greater extent all OSBP/ORPS, are enigmatic proteins 
especially when it comes to their ligand binding properties. For example, in OSBP all 
ligands induce changes in its cellular distribution; however, OSBP ligands are structurally 
very different and induce different biological response.19,101,198 The ORPphilins, in 
particular, are interesting because their structures are the most varied and some like 
itraconazole appear to binding in a unique binding pocket. However, systematic, detailed 
binding studies will allow us to understand the rules that govern specific optimal ligand 
binding. These experiments will require the continued use of [3H]-oxysterol binding 
assays, the production of novel analogs and mutational studies of the OSBP/ORP LBD. 
Also, the ORPphilins themselves must be developed as probes to make sure we are 
studying ligand binding in multiple areas. To ascertain LBD-Ligand interactions, we must 
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produce crystal structure of the human OSBP/ORP LBD bound to ORPphilins and 
endogenous ligands. Incorporating these methodologies will allow us to fully understand 
this protein family, which result in the production of effective novel anti-viral and anti-
cancer compounds.  
However, studying this protein family is limited to two disease states or even 
medicine. For example, oxathipiprolin (Figure 21), which was discovered by DuPont, 
has been approved by the EPA to be used as an agricultural pesticide agent to protect 
grapes and other crops against the infestation of Pseudoperonospora cubensis, which is 
an oomycete microorganism.208 Oxathiapiprolin’s mechanism of action was determined 
to be the inhibition of one of 
the oomycete’s oxysterol-
binding proteins.208 The 
unexpected revelation of an 
OSBP/ORP as the chemical 
target for a microbial pest 
illustrates that the OSBP/ORPs are present in almost all eukaryotic organisms (Figure 
22). Studying the ORPs of other organisms may be a way to develop more anti-fungal 
treatments or compounds that can help fight parasitic infections, like Plasmodium. While 
they may be challenging proteins to work with, they possess a vault of information, and 
their applications appear to be limitless.  
Figure 21: Oxathiapiprolin  
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Figure 22: Domain Graph of OSBP/ORPs From Different Eukaryotes 
 Domain graphs were based off full-length Oxysterol Binding Protein (OSBP) and 
the OSBP-related protein (ORP). The graphs were generated and aligned at the 
beginning of their ligand domain, using DOG2.0. 
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Appendix A: Chapter 2 Supplemental Data 
 
 
 
 
 
 
 
Figure 23: Western Blot of ORP4L-MH, LacZ-MH and OSBP tagless 
The western images of ORP4L-myc-His, LacZ-myc-His, and OSBP-tagless 
transferred from a 7.5% SDS PAGE gel. The image was developed with 
primary anti-myc antibody or anti-OSBP, and HRP conjugated secondary 
antibodies. The ladder is True Blue™ Protein Standard (Gold 
Biotechnology). The membrane was cut in half after transfer because 
different primary antibodies were used. 
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Figure 24: Direct Binding Constant of Human OSBP Tagless and LacZ 
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Figure 25: Binding Curves of OSBP (Top) and ORP4L (Bottom) with 25-
Hydroxycholesterol  
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Figure 26: Binding Curves of OSBP (Top) and ORP4L (Bottom) with OSW-1  
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Figure 27: Binding Curves of OSBP (Top) and ORP4L (Bottom) with 
Itraconazole 
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Figure 28: Binding Curves of OSBP (Top) and ORP4L (Bottom) with 24(R)-
Hydroxycholesterol  
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Figure 29: Binding Curves of OSBP (Top) and ORP4L (Bottom) with 24(S)-
Hydroxycholesterol 
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Figure 30: Binding Curves of OSBP (Top) and ORP4L (Bottom) with 
25(R),27-Hydroxycholesterol 
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Figure 31: Binding Curves of OSBP (Top) and ORP4L (Bottom) with 25(S),27-
Hydroxycholesterol   
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Figure 32: Binding Curves of OSBP (Top) and ORP4L (Bottom) with 22(R)-
Hydroxycholesterol  
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Figure 33: Binding Curves of OSBP (Top) and ORP4L (Bottom) with 22(S)-
Hydroxycholesterol 
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Figure 34: Binding Curves of OSBP (Top) and ORP4L (Bottom) with 
20(S)-Hydroxycholesterol   
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Figure 35: Binding Curves of OSBP (Top) and ORP4L (Bottom) with 7α,25-
Dihydroxycholesterol  
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Figure 36: Binding Curves of OSBP (Top) and ORP4L (Bottom) with 
20(R),22(R)-Dihydroxycholesterol 
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Figure 37: Binding Curves of OSBP with 5α-hydroxy-6-ketocholesterol  
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Figure 38: Binding Curves of OSBP with 19-Hydroxycholesterol 
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Figure 39: Confocal Immunofluorescence Microscopy Images of HCT-116 Cells 
(A-D) OSBP (green) and trans-Golgi (red) were visualized in HCT-116 cells using 
immunofluorescence microscopy. Cells were treated with vehicle (A), 10µM 25-
OHC (B), 10µM 20(S)-OHC (C), 10µM 7α,25-DiOHC (D) for 4 hours and then 
stained using primary antibodies for OSBP (green) and trans-Golgi protein TGN46, 
followed by secondary staining with fluorescent antibodies. Nuclei (blue) were 
stained with DAPI. Scale bars are 10 µm.  
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Figure 40: Binding Curves of OSBP (Top) and ORP4L Bottom with SA-7 
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Figure 41: Binding Curves of OSBP (Top) and ORP4L Bottom with SA-8 
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Figure 42: Binding Curves of OSBP (Top) and ORP4L Bottom 
with SA-9 
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Figure 43: Binding Curves of OSBP (Top) and ORP4L Bottom with SA-11 
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Figure 44: Binding Curves of OSBP (Top) and ORP4L Bottom with SA-12 
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Figure 45: Binding Curves of OSBP (Top) and ORP4L Bottom with SA-16 
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Figure 46: Binding Curves of OSBP (Top) and ORP4L Bottom 
with SA-13 
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Figure 47: Binding Curves of OSBP (Top) and ORP4L Bottom with 
SA-14 
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Figure 48: Binding Curves of OSBP (Top) and ORP4L (Bottom) with SA-2 
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Figure 49: Binding Curves of OSBP (Top) and ORP4L (Bottom) with SA-1 
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Figure 50: Binding Curves of OSBP and ORP4L to 21-
Acetoxypregnenolone 
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Figure 51: Binding Curves of OSBP (Top) and ORP4L (Bottom) to 22-
Azacholesterol 
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Figure 52: Binding Curves of OSBP (Top) and ORP4L (Bottom) 
with U-18666A 
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Figure 53: Binding Curves of OSBP (Top) and ORP4L (Bottom) 
with Paxilline 
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Figure 54: Binding Curves OSBP with Digitoxigenin  
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Figure 55: Binding Curves of OSBP (Top) and ORP4L (Bottom) with 
Ursodeoxycholic Acid 
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1H NMR (500 MHz, Chloroform-d) δ 5.37 (dt, J = 5.1, 1.7 Hz, 1H), 4.60 (dddd, J = 
11.4, 10.2, 6.2, 4.2 Hz, 1H), 2.53 (t, J = 8.9 Hz, 1H), 2.37 – 2.27 (m, 2H), 2.24 – 2.14 
(m, 1H), 2.12 (s, 3H), 2.03 (s, 3H), 2.02 – 1.96 (m, 0H), 1.91 – 1.83 (m, 2H), 1.73 – 
1.53 (m, 5H), 1.53 – 1.40 (m, 3H), 1.28 – 1.10 (m, 3H), 1.01 (s, 3H), 0.63 (s, 3H). 
 
 
 
Figure 56: NMR of Pregnenolone Acetate 
144 
 
 
1H NMR (400 MHz, Chloroform-d) δ 5.37 (dd, J = 5.0, 2.7 Hz, 1H), 4.66 – 4.55 (m, 
1H), 3.73 (dq, J = 9.7, 6.1 Hz, 1H), 2.38 – 2.25 (m, 2H), 2.08 (dt, J = 12.5, 3.5 Hz, 1H), 
2.03 (s, 3H), 2.02 – 1.93 (m, 1H), 1.90 – 1.81 (m, 2H), 1.73 – 1.41 (m, 7H), 1.39 – 1.16 
(m, 4H), 1.14 (d, J = 6.1 Hz, 4H), 1.12 – 1.05 (m, 1H), 1.03 (s, 3H), 1.01 – 0.93 (m, 
1H), 0.77 (s, 3H). 
 
 
 
 
 
 
 
 
Figure 57: NMR of SA-7 
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1H NMR (400 MHz, Chloroform-d) δ 5.38 (d, J = 5.1 Hz, 1H), 4.60 (tt, J = 10.7, 4.7 
Hz, 1H), 3.78 – 3.66 (m, 1H), 2.32 (d, J = 7.0 Hz, 2H), 2.03 (s, 3H), 2.01 – 1.82 (m, 
4H), 1.73 – 1.41 (m, 8H), 1.34 (q, J = 9.1 Hz, 1H), 1.23 (d, J = 6.2 Hz, 4H), 1.20 – 1.04 
(m, 3H), 1.02 (s, 3H), 1.00 – 0.92 (m, 1H), 0.68 (s, 3H). 
 Figure 58: NMR of SA-8 
